D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
CONFIDENTIAL  
INVESTIGATOR  SIGNATURE  
[CONTACT_1738]  #:  Study  D‐PLEX  311 
Protocol  Title:   Phase  III, Prospective,  Multinational,  
Multicenter,  Randomized,  Controlled,  Two‐arm,  
Double  Blind  Study  to Assess  Efficacy  and Safety  
of D‐PLEX  Administered  Concomitantly  with the 
Standard  of Care (SoC),  Compared  to a SoC 
Treated  Control  Arm,  in Prevention  of Post 
Abdominal  Surgery  Incisional  Infection  
Protocol  Version:   [ADDRESS_1194982]  Number:   2020 ‐002325 ‐28  
IND  Number:   [ADDRESS_1194983]  the trial in accordance  with the clinical  trial protocol,  ICH GCP guidelines,  as 
well as local  regulations.  I also accept  respective  revisions  to the clinical  trial protocol  
approved  by [CONTACT_857745].  
This  document  contains  proprietary  and  confidential  information  of PolyPid.  Do  not  copy,  
distribute,  or  share  with  others  without  prior  written  authorization  from  PolyPid  
Principal  Investigator  (print  name)  
Principal  Investigator  (signature)   Date D-PLEX 311 Clinical Trial Protocol P-000066
Protocols Version 6.0
22-2-2022Page 3 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1194984] OF ABBREVIATIONS  ................................................... .............................................  11 
3 TRIAL  PERSONNEL  ................................................... ................................................... ... 13 
3.1 Sponsors  Representatives  ................................................... ...................................  [ADDRESS_1194985] Abdominal  Surgery  Incisional  
Infection  ................................................... ................................................... ..................  29 
5.1.3  Justification  for the Use of D‐PLEX  for Prevention  of Post Abdominal  Surgery  
Incisional  Infection  ................................................... ................................................... .. 29 
5.2 NON ‐CLINICAL  DATA  ................................................... ............................................  30 
5.3 CLINICAL  DATA  ................................................... ................................................... .. 32 
5.4 SAFETY  PROFILE  OF DOXYCYCLINE  ................................................... .......................  33 
5.5 POTENTIAL  BENEFITS  OF D‐PLEX  FOR PREVENTION  OF POST  ABDOMINAL  SURGERY  
INCISIONAL  INFECTION  ................................................... ..................................................  34 
5.6 POTENTIAL  RISKS  OF D‐PLEX  FOR PREVENTION  OF POST  ABDOMINAL  SURGERY  
INCISIONAL  INFECTIONS  AND THEIR  MITIGATIONS  ................................................... ........  34 
5.7 SAFETY  & EFFICACY  SUMMARY  ................................................... ...........................  37 
6 OBJECTIVES  ................................................... ................................................... .............  37 
7 STUDY  ENDPOINTS  ................................................... ................................................... .. 37 
7.1 PRIMARY  EFFICACY  ENDPOINT  ................................................... ............................  37 
7.2 SECONDARY  EFFICACY  ENDPOINTS  ................................................... ......................  38 
7.2.1  Key endpoints:  ................................................... ..............................................  38 
7.2.2  Additional  endpoints:  ................................................... ...................................  38 
7.3 SAFETY  EVALUATION  ................................................... ...........................................  39 
8 TRIAL  DESIGN  ................................................... ................................................... ..........  39 
8.1 OVERALL  DESIGN  ................................................... .................................................  39 
8.2 DESCRIPTION  & JUSTIFICATION  OF THE DURATION  OF TREATMENT,  SUBJECT  
PARTICIPATION  AND TRIAL  FOLLOW ‐UP ................................................... ........................  40     
 
22-2-2022Page 6 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
8.3 SELECTION  OF SUBJECTS  ................................................... ......................................  41 
8.4 INCLUSION  CRITERIA  ................................................... ............................................  41 
8.5 EXCLUSION  CRITERIA  ................................................... ...........................................  41 
8.6 Contraceptive  methods  ................................................... .......................................  43 
8.7 RECRUITMENT  ................................................... ................................................... .. 44 
9 STUDY  PROCEDURES  & SCHEDULE  OF ASSESSMENTS  ...................................................  44 
9.1 STUDY  PROCEDURES  ................................................... ............................................  44 
9.1.1  Informed  Consent  Procedure  ................................................... .......................  44 
9.1.2  Screen  Failure  ................................................... ...............................................  45 
9.1.3  Randomization  / Enrolment  ................................................... .........................  45 
9.1.4  Blinding  ................................................... ................................................... ...... 45 
9.1.5  Emergency  Unblinding  ................................................... .................................  46 
9.1.6  Assessment  of the Infection  Rate ................................................... .................  47 
9.1.7  Management  of Suspected  SSI ................................................... .....................  49 
9.1.8  Safety  Evaluation  ................................................... ..........................................  49 
9.1.9  Adverse  Events  ................................................... .............................................  50 
9.1.10  Laboratory  Examinations  ................................................... ..............................  50 
9.1.11  Central  Laboratory  ................................................... ........................................  50 
9.1.12  Local  Laboratory  ................................................... ...........................................  52 
9.1.13  Bacteriological  Testing  ‐ (Should  be Taken  in Any Case  of Suspected  Infection  
Before  Starting  Antibiotic  Treatment)  ................................................... ........................  52 
9.1.14  Physical  Examination  ................................................... ....................................  53 
9.1.15  Vital Signs  ................................................... ................................................... .. 53 
9.1.16  Medical  History  ................................................... ............................................  53 
9.1.17  Allergy  Questionnaire  ................................................... ...................................  53 
9.1.18  Assessment  of Surgical  Site ................................................... ..........................  53 
9.1.19  ASEPSIS:  (Additional  Treatment,  Serous  Discharge,  Erythema,  Purulent  
Exudate,  Separation  of Deep  Tissue,  Isolation  of Bacteria,  Stay Duration  as Inpatient)  
Scoring  Method  ................................................... ................................................... ....... 54 
9.1.20  Pharmacokinetics  ................................................... .........................................  54 
9.2 STUDY  VISITS  & ASSESSMENTS  ................................................... ............................  55 
9.2.1  Visit 1: Screening  Period  (Day ‐21  Day 0) ................................................... ... 55     
 
22-2-2022Page 7 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
9.2.2  Visit 2: Surgery   Index  Procedure  (Day 0) ................................................... ... 56 
9.2.3  Visits  3  6: Follow ‐Up Visits  (Days  1, 5 ,14 & [ADDRESS_1194986]‐Surgery)  .......................  57 
9.2.4  Unscheduled  Visit(s)  ................................................... .....................................  58 
9.2.5  Visit 7 ‐ End of Study  ([ADDRESS_1194987]‐Surgery)  ...................................................  58 
9.2.6  Study  Assessments  Summary  ................................................... .......................  58 
TABLE  1: STUDY  ASSESSMENTS  ................................................... ......................................  59 
9.3 EFINITION  OF END OF TRIAL  ................................................... ................................  60 
9.4 DISCONTINUATION/WITHDRAWAL  OF PARTICIPANTS  & STOPPI[INVESTIGATOR_857693]  ..........  60 
10 NAME  & DESCRIPTION  OF ALL DRUGS  USED  IN THE TRIAL  ...........................................  61 
10.1  STUDY  TREATMENT  D‐PLEX  ................................................... ..............................  [ADDRESS_1194988]  Handling  (storage  & preparation)  ................................................... ... [ADDRESS_1194989]  Usage  and Dosage  ................................................... ...........................  63 
10.1.5  Contra ‐Indications  ................................................... ........................................  64 
10.1.6  Use in Specific  Populations  ................................................... ...........................  64 
10.1.7  Warnings  and Precautions  ................................................... ............................  64 
10.1.8  Overdose:  Guidance  on the recognition  and treatment  of possible  overdose  
and adverse  drug  reactions  ................................................... ........................................  64 
10.1.9  Packaging  ................................................... ................................................... ... 65 
10.2  CONCOMITANT  MEDICATION  ................................................... ..........................  65 
10.2.1  Medication(s)/  Treatment(s)  Permitted  ................................................... ....... 65 
10.2.2  Medication(s)  Prohibited  During  the Trial ................................................... .... 65 
10.3  PREPARATION  & LABELLING  OF INVESTIGATIONAL  PRODUCT  (IP) .....................  65 
10.4  DRUG  ACCOUNTABILITY  ................................................... ...................................  66 
10.5  RECORDING  & REPORTING  OF ADVERSE  EVENTS  & REACTIONS  .........................  66 
10.6  DEFINITIONS  ................................................... ................................................... .. 66 
10.6.1  Adverse  Event  (AE) ................................................... .......................................  66 
10.6.2  Adverse  Drug  Reaction  (ADR)  ................................................... .......................  67 
10.6.3  Serious  Adverse  Event  (SAE)  ................................................... .........................  67 
10.6.4  Unexpected  Serious  Adverse  Reaction  ................................................... .........  68     
 
22-2-2022Page 8 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
10.7  A serious  adverse  reaction,  the nature,  severity  or outcome  of which  is not 
consistent  with the reference  safety  information  (i.e. Investigator  Brochure  (IB)) in effect  
at the time of its occurrence.   ASSESSMENT  OF ADVERSE  EVENT  .....................................  68 
10.7.1  Severity  ................................................... ................................................... ...... 68 
10.7.2  Causality  ................................................... ................................................... .... 69 
10.7.3  Outcome  ................................................... ................................................... .... 69 
10.7.4  Expectedness  ................................................... ................................................  69 
10.7.5  Seriousness  ................................................... ...................................................  70 
10.8  DOCUMENTATION  AND REPORTING  OF SAE and SSI ..........................................  70 
10.9  TIME  PERIOD  AND FREQUENCY  FOR reporting  AEs .............................................  70 
10.9.1  Procedures  for Recording  & Reporting  Serious  Adverse  Events  ......................  71 
10.9.2  Notification  of Deaths  ................................................... ..................................  71 
10.10  REPORTING  OF S[LOCATION_003]Rs  (Suspected  Unexpected  Serious  Adverse  Reaction)  ...... 71 
10.11  DEVELOPMENT  OF SAFETY  UPDATE  REPORTS  ................................................... . 72 
10.12  THE TYPE  & DURATION  OF THE FOLLOW ‐UP OF SUBJECTS  AFTER  AEs ...............  72 
11 NOTIFICATION  OF PROTOCOL  DEVIATION  ................................................... .................  72 
12 DATA  MANAGEMENT  & QUALITY  ASSURANCE  ................................................... ..........  72 
12.1  CONFIDENTIALITY.................................... ................................................... .........  72 
12.2  DATA  COLLECTION  TOOLS  & SOURCE  DOCUMENT  IDENTIFICATION  ..................  72 
12.3  DATA  HANDLING  & ANALYSIS  ................................................... ..........................  [ADDRESS_1194990]  KEEPI[INVESTIGATOR_1645]  & ARCHIVING.......................................... ..........................................  [ADDRESS_1194991]  15 years  
after  completion  of the study.  ................................................... .......................................  73 
14 STATISTICAL  ANALYSIS  CONSIDERATIONS  ................................................... ..................  74 
14.1  SAMPLE  SIZE AND POWER  ................................................... ...............................  74 
14.1.1  Blinded  sample  size re‐estimation ‐ ................................................... ...............  74 
14.2  ANALYSIS  POPULATIONS  ................................................... ..................................  75 
14.2.1  Intention  to Treat  (ITT) Set ................................................... ...........................  75 
14.2.2  Safety  Analysis  Set ................................................... ........................................  75 
14.2.3  Modified  Intention  to Treat  (mITT)  Set ................................................... .........  75 
14.2.4  Per Protocol  (PP) Set ................................................... ....................................  75 
14.3  STATISTICAL  AND ANALYTICAL  PLANS  ................................................... ..............  76     
 
22-2-2022Page 9 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1194992]  Characteristics  ......................  76 
14.3.2  Primary  Endpoint  Analysis  ................................................... ............................  76 
14.3.3  Secondary  Efficacy  Endpoint  Analysis  ................................................... ...........  77 
14.3.4  Type  1 error  control  ................................................... ......................................  78 
14.3.5  Subgroup  analysis  ................................................... .........................................  79 
14.3.6  Safety  Evaluations  ................................................... ........................................  79 
14.3.7  Handling  of Missing  Data  ................................................... ..............................  79 
14.3.8  Interim  Analyses  ................................................... ...........................................  80 
14.4  NAME  [CONTACT_857819]  ................................................... ... 80 
14.4.1  DATA  MONITORING  COMMITTE  (DMC)  ................................................... ....... 80 
14.4.2  ENDPOINTS  ADJUDICATION  COMMITTEE  (EPAC)  ............................................  [ADDRESS_1194993]  ACCESS  TO SOURCE  DATA  DOCUMENTS  ................................................... ........  81 
16 ETHICS  & REGULATORY  REQUIREMENTS  ................................................... ...................  81 
17 QUALITY  CONTROL  (STUDY  MONITORING)  ................................................... ................  82 
18 QUALITY  ASSURANCE  (QA) ................................................... .........................................  82 
19 INSURANCE  ................................................... ................................................... .............  82 
20 PUBLICATION  POLICY  ................................................... .................................................  82 
21 STATEMENT  OF COMPLIANCE  ................................................... ....................................  83 
22 APPENDICES  ................................................... ................................................... ............  83 
23 REFERENCES  ................................................... ................................................... ............  84 
Appendix  1: ASEPSIS  Score  Assessment  ................................................... .........................  86 
Appendix  2: Modified  Vancouver  Scar Scale  ................................................... ..................  87 
Appendix  3: PK instructions  for Collection  and Processing  ...............................................  88 
Appendix  4: SURGICAL  SITE ASSESSMENT  QUESTIONNAIRE  .............................................  89 
Appendix  5: Charlson  co‐morbidity  index  (CCI)  ................................................... ..............  91 
Appendix  6: DOCUMENT  CHANGE  HISTORY  ................................................... ...................  93 
 
       
 
22-2-2022Page 10 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1194994]  OF  ABBREVIATIONS  
2.1 AE  ‐ Adverse  Event  
2.2 ASEPSIS  ‐ Additional  treatment,  Serous  discharge,  Erythema,  Purulent  exudate,  Separation  
of deep  tissue,  Isolation  of bacteria,  Stay duration  as inpatient  
2.3 ALT(SGPT)  ‐ Alanine  Aminotransferase  
2.[ADDRESS_1194995](SGOT)  ‐ Aspartate  Transaminase  
2.5 AUC   Area  Under  Curve  
2.6 BMI  ‐ Body  Mass  Index  
2.7 Β‐TCP  ‐ β‐ Tri‐Calcium  Phosphate  
2.8 BP   Blood  Pressure  
2.9 CDC  ‐ Center  for Disease  Control  
2.10 CDMS  ‐ Clinical  Data  Management  System  
2.11 CKD  ‐ Chronic  Kidney  Disease  
2.12 CM  ‐ Centimetres  
2.13 CRF  ‐ Case  Report  Form  
2.14 ECRF  ‐ Electronic  Case  Report  Form  
2.15 CRP  ‐ C‐Reactive  Protein  
2.16 CVA  ‐ Cerebro  Vascular  Accident  
2.17 DMC  ‐ Data  Monitoring  Committee  
2.18 DSUR   Development  Safety  Update  Report  
2.19 DSSI  ‐ Deep  Surgical  Site Infection  
2.20 EA  ‐ Enterobacter  Aerogenes  
2.21 EC/IRB  ‐ Ethics  Committee/Independent  Review  Board  
2.[ADDRESS_1194996]  ‐ End Stage  Renal  Disease  
2.23 EU  ‐ European  Union  
2.24 G ‐ Gram  
2.25 GCP  ‐ Good  Clinical  Practice  
2.26 GMP  ‐ Good  Manufacturing  Practice  
2.27 HR   Hear t Rate  
2.28 IAP  ‐ Interim  Analysis  Plan  
2.29 IB ‐ Investigators  Brochure  
2.30 ICF  ‐ Informed  Consent  Form  
2.31 ICH  ‐ International  Council  for Harmonisation  Of Technical  Requirements  For 
Pharmaceuticals  For Human  Use  
2.32 IP ‐ Investigational  Product      
 
22-2-2022Page 11 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
2.33 IPAL  ‐ Investigational  Product  Accountability  Log  
2.34 ISO  ‐ International  Organization  for Standardization  
2.35 ITT  ‐ Intention  to Treat  
2.36 IV  ‐ Intravenous  
2.37 IWRS  ‐ Interactive  Web  Randomization  System  
2.38 LDH  ‐ Lactate  Dehydrogenase  
2.39 MG  ‐ Milligram  
2.40 MIC  ‐ Minimal  Inhibitory  Concentration  
2.41 MITT  ‐ Modified  Intention  To Treat  
2.42 MOH  ‐ Ministry  Of Health  
2.43 MRSA  ‐ Methicillin ‐Resistant  Staphylococcus  Aureus  
2.44 NHSN  ‐ Natio nal Healthcare  Safety  Network  
2.45 NIS  ‐ National  Inpatient  Sample  
2.46 OR  ‐ Operation  Room  
2.47 PI ‐ Principal  Investigator  
2.48 PK  ‐ Pharmacokinetics    
2.49 PLEX  ‐ Polymer ‐Lipid  Encapsulation  Matrix  
2.50 PP  ‐ Per Protocol  
2.51 PT  ‐ Preferred  Term  
2.52 QA  ‐ Quality  Assurance  
2.53 QC  ‐ Quality  Control  
2.54 RBC  ‐ Red Blood  Cell  
2.55 SAP  ‐ Statisti cal Analysis  Plan  
2.56 SAR  ‐ Serious  Adverse  Reaction  
2.57 SAE  ‐ Serious  Adverse  Event  
2.58 SOC  ‐ Standard  of Care  
2.59 SOP  ‐ Standard  Operating  Procedure  
2.60 SSI  ‐ Surgical  Site Infection  
2.61 SSSI  ‐ Superficial  Incisional  Surgical  Site Infection  
2.62 S[LOCATION_003]R  ‐ Suspected  Unexpected  Serious  Adverse  Reaction  
2.63 TEAE  ‐ Treatment  Emergent  Adverse  Event  
2.64 TIA  ‐ Transien t Ischemic  Attack  
2.65 WBC  ‐ White  Blood  Cell 
2.66 WOCBP  ‐ Women  of Childbearing  Potential  
     
 
22-2-2022Page 12 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
3 TRIAL  PERSONNEL  
3.1 SPONSORS  REPRESENTATIVES  
    
   
 PolyPid  Ltd.  
 [ADDRESS_1194997],   
 Petach  Tikva,  4959376  
 Israel     
 Tel:   
   
    
Clinical  Development  Manager  
PolyPid  Ltd.  
[ADDRESS_1194998],   
Petach  Tikva,  4959376  
Israel     
 
 
 
 
 
      
 
22-2-2022Page 13 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
4 SUMMARY  
Study  Number:   Study  D‐PLEX ‐311 
Study  Title:  Phase  III, Prospective,  Multinational,  Multicenter,  Randomized,  
Controlled,  Two‐arm,  Double  Blind  Study  to assess  Efficacy  and 
Safety  of D‐PLEX  Administered  Concomitantly  with the Standard  
of Care (SoC),  compared  to a SoC treated  control  arm,  in 
prevention  of post abdominal  surgery  incisional  infection.  
Phase:   Phase  III 
Objectives:   ● To assess  the anti‐infective  efficacy  of D‐PLEX  administered  
concomitantly  with the Standard  of Care  (SoC)  over a period  of 
[ADDRESS_1194999] operation,  by [CONTACT_857746]  
(SSI),  defined  as superficial  and/or  deep  infection  in the target  
incision,  compared  to the SoC treated  control  arm. 
● To assess  the safety  of D‐PLEX  administered  concomitantly  with 
the Standard  of Care (SoC) . 
Number  of Centers:   About    sites in the US, EU and Israel  
Subject  Population:   Male  and female,  [ADDRESS_1195000]  the demographic  
for clinically  relevant  population  with regards  to: age, gender,  
race and ethnicity.  This population  reflects  the US and Europe  
population  undergoing  abdominal  colorectal  surgeries.  
Number  of Subjects:   Minimum  of 950 subjects  will be enrolled  and randomized  into 
the study,  with a maximum  of 1400  subjects.  
The final number  of subjects  will be determined  following  a 
comparative  interim  analysis  for an early  efficacy  or futility  stop 
or unblinded  sample  size re‐estimation:  when  about  750 
subjects  will complete  their  30 days (1 month)  follow‐up and 
evaluated  for primary  endpoint.      
 
22-2-2022Page 14 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195001]:   D‐PLEX  is a new formulation  of extended  release  of Doxycycline.  
Each  5g D‐PLEX  vial contains     Doxycycline  free base  
( ),  which  is equivalent  to    Doxycycline  hyclate  
). 
D‐PLEX  is supplied  as a sterile  powder  to be reconstituted  to 
paste  in the operating  room  using  standard  techniques.  D‐PLEX  
is intended  for single  administration.  
The non‐active  components  of the extended  release  antibiotic  
formulation  are   
 
All formulation  components  are biodegradable.  
Indication:   D‐PLEX  is indicated  for prevention  of post abdominal  surgery  
incisional  infection.  
Other  Drugs  Required  for 
the Study:  NA 
Standard  of Care:   The SoC for prophylactic  antibiotic  treatment  is based  on 
international  guidelines3. It will be consistent  and standardized  
for all sites in the clinical  study  and is composed  of IV antibiotic  
prior  to surgery,  with or without  mechanical  bowel  preparation  
in the preceding  several  days.  Each  site will use the same  pre‐
defined  SoC for all its subjects  during  the study.   
IV antibiotic  treatment  will be composed  of the 1st or 2nd 
generation  of Cephalosporin  family  plus Metronidazole  given  
within  60 minutes  prior  to surgery  and should  be discontinued  
maximum  24‐hour  post‐surgery.  In case of allergy  to the 
Cephalosporin/  Penicillin  families  or Metronidazole,  other  IV 
antibiotic  may be used.  Pre‐operation  prophylactic  oral 
antibiotic  is not allowed.   Mechanical  bowel  preparation  (use of 
a laxative  (polyethylene  glycol,  sodium  phosphate,  or a 
magnesium  citratebased  regimen)  or a high‐volume  enema)  
will be at the discretion  of the PI [INVESTIGATOR_857694]’s  SOP.   Subjects  
will be stratified  to 2 cohorts  according  to usage  of mechanical  
bowel  preparation  prophylactic  care (Yes or No) and by [CONTACT_11338]  
(US or Europe  + Israel).     
Dose  Administration:   D‐PLEX  dose  is individualized,  pending  length  of the abdominal  
target  incision,  2‐3 vials (5g each,  a total  max of 15g) in a single      
 
22-2-2022Page 15 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
application.  
Application  will be done  at the time of initial  closure  of the 
abdominal  wall target  incision.  Following  closure  of the fascia,  
D‐PLEX  reconstituted  paste  will be applied  on the fascia  suture  
line, followed  by [CONTACT_857747]  (including  muscle,  fat and 
dermis).  D‐PLEX  will not be applie d on top of the skin (suture  
line).  
Duration  of Dosing:   D‐PLEX  is administered  as a single  application.  
The active  ingredient  (Doxycycline)  is continuously  released  for 
approximately  4 weeks.  
Study  Design:     This is a phase  III, prospective,  multinational,  multicenter,  
randomized,  controlled,  two‐arm,  double  blind  (participant  and 
outcome  assessor)  study.  The study  population  includes  male  
and female,  [ADDRESS_1195002]  1 abdominal  incision  that 
is > 10 cm (target  incision).   
Subjects  who meet  the inclusion  criteria  and none  of the 
exclusion  criteria  and who provide  a signed  Informed  Consent  
Form  will be enrolled  in the study.  
Subjects  will be randomized  into either  the investigational  arm 
(D‐PLEX  + SoC) or to the control  arm (SoC only)  in a 1:1 ratio.  
Subjects  will be stratified  by [CONTACT_857748]  (prophylactic  IV antibiotic  with mechanical  bowel  
preparation  or prophylactic  IV antibiotic  without  mechanical  
bowel  preparation)  and by [CONTACT_11338]  (US or Europe  + Israel).  
The sponsor,  the outcome  assessor,  the subjects  and all staff 
involved  in the collection  and recording  of the clinical  and 
laboratory  data,  based  on which  the independent  adjudication  
committee  will perform  their  assessment,  will be blinded  to the 
treatment  assignment.  The OR staff will be trained  to maintain  
in confidence  the treatment  assignment  and not to disclose  it to 
other  staff members.  In addition,  all aspects  of data 
management  and clean ‐up will be done  using  blinded  datasets.      
 
22-2-2022Page 16 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
Subjects  randomized  to the investigational  arm will be treated  
with D‐PLEX  during  the surgery  (index  procedure),  as an adjunct  
to the SoC (see below).  D‐PLEX  will be applied  during  the closure  
of the abdominal  target  incision.  D‐PLEX  will not be re‐
administered  if any reintervention  occurs.   
Subjects  randomized  to the control  arm will be treated  only with 
prophylactic  IV antibiotic  according  to SoC. Pre‐operation  
prophylactic  oral antibiotic  is not allowed.   Mechanical  bowel  
preparation  will be at the discretion  of the PI [INVESTIGATOR_857694]’s  SOP 
(see also section  8.1).   
For both  arms  the prophylactic  SoC will be consistent  and 
standardized  for all sites in the clinical  study.  Each  site will use 
the same  pre‐defined  SoC for all its subjects  during  the study.    
Post‐operative  care (excluding  prophylactic  antibiotics)  will be 
performed  per site SoC. Post‐operative  resumption  of activity  is 
at the discretion  of the Investigator,  based  on the subjects  
medical  condition.  
Doxycycline  pharmacokinetic  sampling  will be collected  in selected  
sites from  all randomized  subjects  in these  sites (sites  from  Czech  
Republic  will not participate  in the PK sub‐study).  About    series  of 
samples  per set will be analyzed.  About  series  will be 
analyzed  from subjects  receiving  2 vials,  about   series  will be 
analyzed  from  subjects  receiving  3 vials.   
Spontaneous  Adverse  Events  (AEs)  including  death  will be 
recorded  throughout  the study.  Pregnancy  will be reported  using  
a specific  form  and will be followed  up until resolution.   
The planned  clinical  program  will establish  the efficacy  and 
safety  of D‐PLEX  by [CONTACT_857749]  30 days after  surgical  
index  procedure.  All subjects  will be followed  for an overall  of 60 
days for safety.  
Primary  Efficacy  Endpoint:  
● Infection  rate as measured  by [CONTACT_857750],  
occurring  within  [ADDRESS_1195003] abdominal  surgery  and     
 
22-2-2022Page 17 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
determined  by a blinded  independent  adjudication  
committee.  
[abdominal  incisional  infection  is defined  as Deep  Incisional  
Surgical  Site Infection  (DSSI)  and/or  Superficial  Incisional  
Surgical  Site Infection  (SSSI)].  
All‐cause  mortality  and re‐intervention  at the primary  incision  
site (target)  due to  suspected  SSI or due to poor  wound  healing,  
including  wound  dehiscence  (as verified  by [CONTACT_857751]),   within  [ADDRESS_1195004] index  surgery  will 
be analysed  as treatment  failure.  
Reinterventions  for other  reasons  likely  unrelated  to the initial  
treatment  (e.g. anastomosis  leaks,  intra abdominal  hemorrhage,  
bowel  obstruction),  will not be considered  as treatment  failure  
in  the primary  analysis  of the primary  endpoint.  These  events  
will be considered  as treatment  failure  in a sensitivity  analysis.  
Reintervention  is defined  as re‐opening  of the surgery  incision,  
used  for the original  index  surgery,  in the operation  room  (OR).  
An independent  and blinded  adjudication  committee  will review  
each  case suspected  for SSI and will adjudicate  if meets  the SSI 
endpoint  criteria.    
Secondary  Efficacy  Endpoints:  
Key endpoints:  
● Infection  rate as measured  by [CONTACT_857752],  
occurring  within  [ADDRESS_1195005] abdominal  index  surgery  and de‐
termined  by a blinded  and independent  adjudication  commit ‐
tee. 
● Number  (percent)  of subjects  with at least  1 score  of 
ASEPSIS  > 20, within  [ADDRESS_1195006] abdominal  index  surgery. 
Additional  endpoints:  
● Incidence  of SSSI during  [ADDRESS_1195007] index  surgery.  
● Incidence  of DSSI during  [ADDRESS_1195008] index  surgery.  
● All‐cause  mortality  rate within  [ADDRESS_1195009] randomization.      
 
22-2-2022Page 18 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
● All‐cause  mortality  rate within  [ADDRESS_1195010] randomization.  
● Time  to adjudicated  SSI during  [ADDRESS_1195011] index  surgery.  
● Number  (percent)  of subjects  re‐admitted  during  [ADDRESS_1195012]‐surgery  (for any reason)  that have  experienced  
adjudicated  SSI during  this re‐admission.  
● Number  (percent)  of subjects  who experienced  at least  1 
surgical  re‐intervention  due to adjudicated  SSI during  [ADDRESS_1195013]‐surgery.  Re‐intervention  is defined  as re‐opening  
of the surgery  incision,  used  for the original  index  surgery,  in 
the operation  room  (OR).  
 
SSI  related  Additional  Endpoints : 
● Number  (percent)  of subjects  with adjudicated  SSI where  at 
least  one Doxycycline ‐resistant  bacteria  has grown  in bacte ‐
riology  tests   
● Number  (percent)  of Doxycycline ‐resistant  bacteria  out of all 
bacteria  that were  cultured  during  bacteriology  test from  
subjects  with adjudicated  SSI. 
● Number  (percent)  of subjects  who experienced  adjudicated  
SSI during  [ADDRESS_1195014]‐surgery  that was treated  by [CONTACT_857753].  
● Number  of IV antibiotic  treatment  days,  administered  to 
subjects  who experienced  adjudicated  SSI during  [ADDRESS_1195015]‐surgery.   
● Average  of subjects  cumulative  ASEPSIS  assessment  score  
(AUC)  for subjects  with adjudicated  SSI during  [ADDRESS_1195016]‐
surgery.   
● Number  (percent)  of subjects  with at least  1 score  of 
ASEPSIS  > [ADDRESS_1195017] abdominal  index  surgery.  
Identification  of an SSI  will  be  based  on  CDC/NHSN  Patient  Safety  
Component  Manual  criteria  (January  2020,  chapter  9) 
Safety  Evaluation:  
The following  safety  parameters  will be evaluated  in this trial: 
● AEs, physical  examinations  & vital signs.      
 
22-2-2022Page 19 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
● Incisional  wound  healing  (including  Hernia)  will be assessed  
by a blinded  Investigator,  using  a visual  examination  (part  of 
a Surgical  Site Assessment  questionnaire)  as well as 
Modified  Vancouver  Scar Scale  wound  assessment  
questionnaires.  
● Safety  laboratory  parameters:  hematology,  chemistry.  
It is expected  that each  subject  will be in the study  for 
approximately  60 days.  
 
Inclusion  Criteria:   Subjects  who meet  all of the following  criteria  will be eligible  to 
participate  in the study:  
1. Subjects  undergoing  an elective  colorectal  surgery  involving  
resection,  with or without  a stoma  formation,  that includes  
at least  1 abdominal  incision  that is > 10cm  (target  incision).   
2. Subjects  are preoperative  hemodynamically  stable  
(BPf180/110  and 90/60  mmHg,  and HRf100 and 60 bpm,  
and temperature  f38.50C and 35.50C). 
3. Male  or non‐pregnant  female.  
4. Female  of child ‐bearing  potential  should  have  a negative  
pregnancy  test (serum  or urine  dipstick)  prior  to index  
procedure.  
 Note:  All  female  subjects  of child ‐bearing  potential  must  agree  to 
use  a highly  effective  method  of contraception  consistently  and  
correctly  for  the  duration  of the  study  (see  Section  8.6   
CONTRACEPTIVE  METHODS).  
5. Subjects’  age [ADDRESS_1195018] randomization  
Exclusion  Criteria:   Subjects  who meet  any of the following  exclusion  criteria  are 
prohibited  from  participating  in the study:  
1. Subjects  with suspected/diagnosed  intestinal  perforation,   
intra ‐abdominal  abscess,   or any emergency/urgent  
colorectal  surgery  with acute  intestinal  obstruction  (ex. toxic      
 
22-2-2022Page 20 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
colitis,  ileus/sub ‐ileus,  megacolon,  diverticulitis,  volvulus,  
ect.)  
2.   Subjects  who underwent  an intra ‐abdominal  surgery  within  the 
last [ADDRESS_1195019] 1 week  prior  to 
randomization,  excluding  pre‐operative  prophylaxis.  
4. Subjects  undergoing  concomitant  major  procedures  in 
addition  to the abdominal  surgery,  including  conco mitant  
repair  of ventral  hernia.   
Salpi[INVESTIGATOR_8936] ‐oophorectomy  and cholecystectomy  are allowed.    
5. Subjects  who received  any anti‐cancer  treatment  within  the 
last [ADDRESS_1195020] 4 weeks  prior  to 
randomization.  
8. Subjects  with known  allergy  to Doxycyclin e and/or  to the 
tetracycline  family  of drugs  or to the D‐PLEX’s  excipi[INVESTIGATOR_840].  
9. Subjects  with known  allergies  to more  than  3 substances  (an 
allergy  questionnaire  will be completed  during  the screening  
process).  
10. Subjects  with history  of severe  allergic  reaction  to any 
substance,  having required  treatment  with intravenous  
steroids/intramuscular  epi[INVESTIGATOR_238],  or who in the opi[INVESTIGATOR_857695].  
11. Subjects  with End Stage  Renal  Disease  (ESRD/  CKD stage  5). 
12. Subjects  with severe  hepatic  impairment.  
13. Subjects  with chronic  urticaria.  
14. Subjects  diagnosed  with CVA within  the past 6 months  prior  
to randomization.      
 
22-2-2022Page 21 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
15. Subjects  who underwent  any abdominal  surgery  and current  
planned  index  surgery  involves  re‐opening  the scar of a prior  
abdominal  surgery  performed  within  the last [ADDRESS_1195021]  with an active  malignancy,  other  than resectable  
non‐metastatic  colorectal  cancer,  that is the reason  for the in‐
dex surgery,  or carcinoma  in situ (or other  cancer  "in situ = 
Stage  0"), or squamous  cell carcinoma  of the skin, or basal  cell 
carcinoma  of the skin, or a malignan cy that has not been  in 
complete  clinical  remission  and without  maintenance  chemo  or 
immunother apy for at least  3 years.   
17. Subjects  with other  concurrent  severe  and/or  uncontrolled  
medical  condition.  
18. Psychiatric  or any other  disorder  that compromises  ability  to 
provide  informed  consent  for participation  in this study.  
19. Chronic  alcoholic  or drug  abuse  subjects.  
20. Pregnant  or breast ‐feeding  women  or women  of child ‐
bearing  age who refuse  or are prohibited  of using  an 
effective  contraceptive  method  of birth  control  throughout  
study  participation,  including  the safety  follow ‐up period.  
21. Subjects  who received  any investiga tional  drug  within  
30 days or 5 half‐lives prior  to randomization  to the study  
(whichever  is longer)  and through  the study.  
22. Subjects  participating  in any other  interventional  study.  
23. Subjects,  who in the opi[INVESTIGATOR_857696],  are not eligible  
to participate  in the study  and/or  to comply  with the 
protocol  requirements  (e.g. due to a cognitive  or medical  
condition).  
Sample  Size:  The study  will enrol  a minimum  of [ADDRESS_1195022]  to the primary  efficacy  endpoint.  It was assumed  that the 
SSI rate in the SOC arm would  as high as 16% range.  The study  
predefined  assumption  is that D‐PLEX  +SOC will have  effect  of 50% 
on this rate (halving  infection  rate)  relative  to SOC alone,  thus 8% 
infection  rate in D‐PLEX+SOC  arm.  Assuming  rate equal  to   for     
 
22-2-2022Page 22 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195023]  to 30‐day treatment  failure  due to all‐cause  
mortality   or re‐intervention  in the target  incision  due to suspected  
SSI or due to poor  wound  healing,  including  wound  dehiscence,  the 
assumed  treatment  failure  rates  were     and  , for SOC and 
DPLEX+SOC,  respectively.  It was calculated  that a sample  of 882 
total  subjects  provides  90% power  to detect  the assumed  
difference  in treatme nt failure  rates.  The calculation  was based  on 
a chi square  test, and to account  for the planned  interim  analysis  
for efficacy  (to be performed  with two‐sided  α=0.01),  a 
conservative  two‐sided  α=0.04  level  of significance  was employed.    
In order  to account  for an anticipated  about  5% lost‐to‐follow ‐up 
rate,  a minimum  of 950 subjects  (475/treatment  arm)  will be 
enrolled.   
One comparative  interim  analysis  for an early  efficacy  or futility  
stop or unblinded  sample  size re‐estimation  will be conducted  
when  about  750 subjects  will complete  the 1‐month  follow ‐up and 
evaluated  for the primary  endpoin t. The interim  analysis  will 
include  a group  sequential  design  stoppi[INVESTIGATOR_857697],  combined  with unblinde d sample  size re‐assessment  based  
on the Promising  Zone  approach.  
The outcome  of this interim  analysis  will be either  early  stoppi[INVESTIGATOR_857698],  or continuation  to planned  final (950 
subjects)  or continue  with sample  size increased  up to maximal  size 
of 1400  only if the comparative  result  falls in a predefined  
Promising  Zone.  The interim  decision  will be made  by [CONTACT_857754] a pre‐planned  interim  analysis  plan,  
and comparative  information  will be maintained  confidential  within  
the independent  statistician  until the study  finally  unblinded.   
Randomization:   Subjects  will be randomized  to either  the investigational  arm (SoC + 
D‐PLEX)  or to the control  arm (SoC only)  in a 1:1 ratio.  
Randomization  will be stratified  by [CONTACT_857755]  (prophylactic  IV antibiotic  with mechanical  
bowel  preparation  or prophylactic  IV antibiotic  without  mechanical  
bowel  preparation)  and by [CONTACT_11338]  (US or Europe  + Israel).  
Statistical  Methods:  The following  analysis  populations  will be defined  for the study:   
Intention  to  Treat  (ITT): The ITT analysis  set will consist  of all 
subjects  who have  been  randomized  to receive  either  D‐PLEX  +     
 
22-2-2022Page 23 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
SoC or SoC alone.  In this analysis  set, treatment  will be assigned  
based  on the treatment  to which  subjects  were  randomized,  
regardless  of which  treatment  they actually  receive.   
Modified  Intent  to  Treat  (mITT):  The mITT  analysis  set is a subset  
of the ITT set and will consist  of all subjects  randomized  and 
treated  with D‐PLEX  + SoC or SoC alone  who underwent  the index  
surgery  and have  no eligibility  criteria  deviation.  In this analysis  
set, treatment  will be assigned  based  on the treatment  to which  
subjects  were  randomized,  regardless  of which  treatment  they 
actually  received.  The exclusion  from  the mITT  population  will be 
determined  in a blinded  manner  prior  to database  lock. Subjects  
who will die during  the study  will not be excluded  from the mITT  
population.  
Per  Protocol  (PP):  The PP analysis  set is a subset  of the mITT  set 
and will consist  of all subjects  in the mITT  set that have  no major  
protocol  deviations  and were  assessed  for the primary  endpoint  
(i.e. completed  the Day [ADDRESS_1195024]‐surgical  SSI, or death   or re‐intervention  in the 
index  surgery  due to suspected  SSI or due to poor  wound  healing,  
including  wound  dehiscence).  
Safety:  The safety  analysis  set will consist  of all subjects  who have  
been  randomized  and treated.  In this population,  treatment  will 
be assigned  based  upon  the treatment  the subjects  actually  
received,  regardless  of the treatment  to which  they were  
randomized.   
The analysis  of the primary  and key secondary  effica cy endpoints  will 
be performed  on the ITT, mITT  and PP populations,  with the ITT 
population  serving  as the primary  analysis  set. Analyses  of additional  
efficacy  endpoints  will be performed  on the populations  as descri bed 
in the Statistical  Analysis  Plan (SAP)  for the study.   
Analyses  of safety  will be performed  on the safety  population.   
 
Analysis  of  Primary  Efficacy  Endpoint  
The primary  analysis  will be based  on a composite  treatment  failure  
(Yes/No)  variable  indicating  if a subject  had at least  one of the 
following  treatment ‐failur e events:  SSI, as determined  by a blinde d and 
independent  adjudication  committee,  within  [ADDRESS_1195025] abdominal  
surgery,  or all‐cause  mortality  by 30 days.  Also re‐interventions  at the     
 
22-2-2022Page 24 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195026] index  
surgery  and indeterminate  outcome  (due to missing  data)  will be 
considered  a treatment  failure  for the primary  ITT analysis.  The 
number  and proportion  of subjects  with treatment ‐failure  will be 
tabulated  per treatment  group.  A 95% confidence  interval  will be 
constructed  for each  proportion.  A Cochran  Mantel ‐Haenszel  (CMH)  
test will compare  the proportion  between  the two groups,  using  the 
study  stratification  factors  used  for randomization,  and corresponding  
risk difference  estimate  will be presente d with 95% confidence  interval  
(using  the method  of MantelHaensze l stratum  weights,  as applied  in 
the COMMONRISKDIFF  option  in the SAS FREQ  procedure).  The 
following  hypotheses  will be tested  for a significant  difference  in the 
primary  endpoint  proportions  between  D‐PLEX+SoC  (PDPLEX) and SoC 
(PSoC) treatment:  
H0: PDPLEX = PSoC 
vs. 
H1: PDPLEX ≠ PSoC 
The significance  level  for this test will be two‐sided  5%. In the case of 
small  number  of events  (less than 5 events  in any study  arm),  the 
Fisher  exact  test will be used.  
The number  and percent  of each  of the failure  types  will be described  
by [CONTACT_19313].  
Analysis  of  Safet y 
All AEs will be coded  using the MedDRA  coding  dictionary.  The number  
and proportion  of subjects  reporting  at least  one treatment  emergent  
adverse  event  (TEAE)  and the number  and proportion  of subjects  
reporting  at least  one TEAE  by [CONTACT_857756].  This analysis  will be repeated  for 
serious  AEs (SAEs)  and for treatment ‐related  AEs. Additi onal 
summaries  of TEAEs  will be performed  by [CONTACT_857757].     
Vital sign measurements  and clinical  laboratory  parameters  will be 
summarized  via descriptive  statistics  (mean,  standard  deviation,  
median,  minimum,  maximum,  and number  of non‐missing  
observations)  for each  post‐treatm ent time point.  Shift tables  will be     
 
22-2-2022Page 25 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
 
   constructed  for physical  exams  to display  any changes  in body  system  
findings  over time.  Responses  to the Modified  Vancouver  Scar Scale  
will be summarized  with counts  and proportions  by [CONTACT_857758].  
All other  analyses  of efficacy  and safety  will be conducted  as described  
in the main  body  of this clinical  study  protocol.  
Interim  analysis:   One un‐blinded  comparative  interim  analysis  will be conducted  after  a 
total  of about  N=[ADDRESS_1195027]  been  assessed  for the primary  
efficacy  endpoint.   The interim  analysis  will include  a group  sequential  
design  stoppi[INVESTIGATOR_857699],  combined  with unblinded  
sample  size re‐assessment  based  on the Promising  Zone approach.  
The outcome  of this interim  analysis  will be either  early  stoppin g for 
efficacy  or futility,  or continuation  to planned  final (950 subjects)  or 
continue  with sample  size increased  up to maximal  size of 1400  only if 
the comparative  result  falls in a predefined  Promising  Zone.      
 
22-2-2022Page 26 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195028]  
[IP_ADDRESS]  Product  Name  
D‐PLEX  (Doxycycline/Polymer ‐Lipid  Encapsulation  MatriX)  
5g D‐PLEX  per vial contains     w/w Doxycycline  hyclate  equivalent  to  ( )  
Doxycycline  free base.  
[IP_ADDRESS]  Drug  Substance  Chemical  Name  [CONTACT_857820] 2‐Naphthacenecarboxamide,  4‐
(dimethylamino) ‐1,4,4a,5,5a,  6,11,12a ‐octahydro ‐3,5,10,12,12a ‐pentahydroxy ‐6‐methyl ‐
1,11‐dioxo ‐, monohydrochloride,  compound  with ethanol  (2:1),  monohydrate,  [4S‐
(4α,4aα,5α,5aα,6α, 12aα)]‐ Doxycycline  Hyclate  chemical  structure  is shown  in Figure  1 
below.  
 
Figure  1: Chemical  Structure  of  Doxycycline  Hyclate  
 
Molecular  Formula:  C22H24N2O8  HCl  0.5H 2O  0.5C 2H5OH 
Molecular  Weight:  512.9  
[IP_ADDRESS]  Proposed  Indication  
D‐PLEX  is indicated  for prevention  of post abdominal  surgery  incisional  infection.  
[IP_ADDRESS]  Dosage  Form,  Route  of  Administration,  and  Dosing  Regimen  (Frequency  and  Duration)  
Dosage  form:  D‐PLEX  is a biodegradable,  extended ‐release  formulation  of Doxycycline  (as 
doxycycline  hyclate)  supplied  as a sterile  powder  for reconstitution  and application  as 
paste,  and intended  for a single use. D‐PLEX  is reconstituted  with 2‐5ml of sterile  saline  
solution  to form  a paste.  
Each  vial contains  5g of D‐PLEX.  The total  percentage  of Doxycycline  in D‐PLEX  in the initial  
clinical  formulation  is    Doxycycline  which  is equivalent  to    Doxycycl ine hyclate.  
    
 
22-2-2022Page 27 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195029]  frequent  complications  in open  abdominal  
surgeries,  and they represent  a significant  cause  of mortality  and morbidity.  Approximately  ten 
million  (10,000,000)  abdominal  surgeries  are performed  annually  in the US; of these,  7.1 
million  (7,100,000)  are general  (gastroenterological)  surgeries  which  include  575,000  
colorectal  resection  surgeries1,2, 2.9 million  (2,900,000)  gynecological  surgeries,  and 608,000  
urological  surgeries.  
The SSI rate ranges  from  approximately  5.0% ‐30.0%  of abdominal  soft tissue  surgeries.  SSIs 
occur  in up to 4.0%  of hysterectomies3,  30.0%4 of colorectal  surgeries  and approximately  6.8%  
in urological  procedures5. Chemotherapy  and other  immuno ‐suppressive  medications  affect  
the function  of the immune  system  and have  the potential  to increase  the SSI rate6. 
SSIs are classified  as superficial  incisional  if limited  to the skin and subcutaneous  tissue,  or 
deep  incisional  when  involving  the fascia  and muscle.  These  infections  are classified  as organ  
space  when  involving  an organ  within  the body  cavity  (i.e., below  the fascia).  Such  organ  space  
infections  are usually  manifested  as abscess7,8. Deep  tissue  and organ  space  surgical  site 
infections  are less frequently  encountered  than  superficial  infections,  but are associated  with 
greater  morbidity/mortality,  more  readmission  rates,  longer  hospi[INVESTIGATOR_857700],  long term  antibiotic  
treatment  and increased  overall  hospi[INVESTIGATOR_307] ‐associated  costs  when  compared  to superficial  
surgical  site infections.  Although  superficial  wound  infections  are more  reliably  treate d with 
systemic  and/or  topi[INVESTIGATOR_857701],  they can lead to clinically  
important  complications  such  as non‐healing  wounds,  systemic  infections,  surgical  site revision  
surgeries,  and, if hospi[INVESTIGATOR_857702]‐longed,  an increased  risk of developi[INVESTIGATOR_857703]‐infection  
with antimicrobial ‐resistant  pathogens.   
While  many  SSIs are uncomplicated,  others  may be severe  and more  challe nging  to manage,  
such as necrot izing deep  soft tissue  infections.  The latter  often  requires  extensive  surgical  
debridement,  multiple  reoperations,  and can be life‐threatening7. 
5.1.3 Justification  for  the  Use  of  D‐PLEX  for  Prevention  of  Post  Abdominal  Surgery  
Incisional  Infection  
D‐PLEX  represents  a novel  formulation  of Doxycycline  that improves  the potential  for the 
prevention  of post abdominal  surgery  incisional  infections  over currently  utilized  preventive  
measures.   Such  measures  include:  (a) additionally  applied  mechanical  measures;  (b) 
administering  prophylactic  antibiotics  prior  to incision;  (c) clippi[INVESTIGATOR_857704]; (d) maintaining  normal  body  temperature  and oxygen  supplementation  
perioperative ly, and achieving  adequate  glycemic  control7,911; (e) introduction  of a sterile  area 
in the operating  room  in order  to restrict  movement,  and increased  sterile  airflow  and air ex‐
change  in the proximity  of the patient;  and (f) wearing  specialized  gowning  by [CONTACT_14085]      
 
22-2-2022Page 29 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
(space  suits)  to prevent  airflow  from  the surgeon  onto  the patient.   While  these  measures  
have  reduced  the rate of infection,  they have  not completely  eliminated  it8,12. Therefore,  the 
prevention  of post abdominal  surgery  infection  represents  an unmet  medical  need.  
Part of the reason  for the persistence  of these  types  of infections  despi[INVESTIGATOR_857705]  a local  hematoma  forms  at the surgical  site following  surgery.  This is a 
wet environment  that encourages  bacterial  growth.  In an attempt  to reduce  the hematoma,  
strict  homeostasis  and drainage  are used.  However,  drains  also constitute  a risk for bacterial  
introduction.  In addition,  the blood  supply  and lymph  fluid at the hematoma  site are 
disrupted.  Therefore,  systemic  antibiotics  and immune  defences  have  impaired  ability  to reach  
the affected  areas,  causing  these  areas  to be more  susceptible  to proliferation  of bacteria  and 
subsequent  development  of infection.  With  low local  prophylactic  antibiot ic concentrations,  
there  is a risk of developi[INVESTIGATOR_857706].   Raising  the systemic  antibiotic  dose  
to improve  local  exposures  may cause  systemic  toxicity.  In an attempt  to over‐come  this 
problem,  some surgeons  apply  antibiotics  locally  before  closing  of the incision.  This antibiotic  
treatment  is effective  for very short  durations  of 1‐2 hours  and does  not prevent  development  
of bacterial  infection1316. In addition,  the American  Society  of Health ‐System  Pharmacists,  
Surgical  Infection  Society,  Infectious  Diseases  Society  of America,  and Society  for Healthcare  
Epi[INVESTIGATOR_857707],  the use of currently  
available  topi[INVESTIGATOR_857708]17. A product  such  as D‐PLEX  that provides  
sustained  local  high levels  of Doxycycline  has the potential  of achieving  a reduction  in infection  
not achievable  with present  available  products  or procedures.    
As indicated  above,  D‐PLEX  is a new extended ‐release  formulation  of Doxycycline  for 
administration  in the abdominal  sites following  surgery.  D‐PLEX  releases  Doxycycline  
immediately  upon  prod uct administration  and during  approximately  four weeks  following  
administration.  This is the period  in which  most  of the laparotomy  colon  surgical  site infection  
occur8. During  this period,  the expected  local  Doxycycline  concentration  from  D‐PLEX  is well 
above  the minimal  inhibitory  concentration  (MIC)  of sensitive  organisms.  By [CONTACT_857759]‐administration,  D‐PLEX  is intended  to be effective  for prevention  of 
abdominal  surgery  site infections.  
5.2 NON ‐CLINICAL  DATA  
Non‐clinical  pharmacology  studies,  performed  to demonstrate  D‐PLEX  antimicrobial  activity,  
include  the following:  
● Three  studies  in rabbit  abdominal  incision  site infection  model  (each  with a different  
clinically  relevant  bacteria:  Methicillin ‐Resistant  Staphylococcus  Aureus  (MRSA),  
Enterobacter  aerogenes  (EA),  Enterococcus  feacium  (VRE))  showed  that D‐PLEX  at an applied  
dose  comparable  to 5g administered  to a 70kg  adult  on a mg/kg  basis,  demonstrates  
reduction  of infection  (as reflected  in lesser  clinical  signs,  no incidence  of systemic      
 
22-2-2022Page 30 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
temperature  rise together  with approximately  3‐4 log bacterial  load lower  than  groups  that 
received  only bacteria  with or without  placebo).  
● In vitro  antimicrobial  studies  demonstrated  D‐PLEX  ability  to reduce  the load of six clinically  
relevant  bacteria.  
● These  findings  support  the claim  of antibacterial  activity  of D‐PLEX  in prevention  of 
infections  in soft tissue  environme nt in human.  
Non‐clinical  pharmacokinetic  studies  were  performed  to demonstrate  Doxycycline  local  and 
systemic  concentration  after  its administration.  
● According  to a local  PK study  in a rabbit  abdominal  surgical  incision  model,  the Doxycycline  
concentrations  in the abdominal  incision  area are maintained  for considerable  time above  
the MIC value  of sensitive,  clinically relevant  bacterial  species.  A high concen tration  of 
Doxycycline  is achieved  up to ~5 hours  after  D‐PLEX  administration  (>30µg/mL).  This is 
followed  by [CONTACT_857760]  ~ 3‐5µg/mL  
that is maintained  for approximately  30 days.  These levels  are well above  the MIC of the 
sensitive  strain,  Staphylococcus  aureus  (MIC  of 1µg/mL).  
● D‐PLEX’s  ability  to release  Doxycycline  for a period  of at least  29 days in vivo was shown  in 
rats after  subcutaneous  administration  of D‐PLEX.    
Non‐clinical  safety  and toxicity  studies,  include  the following:  
5.2.1 A safety  and toxicity pi[INVESTIGATOR_857709]  D‐PLEX  was administered  into an abdominal  
incision  in miniature  swine,  shows  that administration  of D‐PLEX  comparable  on a 
mg/kg  basis  to 20g D‐PLEX  dose  administered  to a 70‐kg adult,  demonstrates  no 
macroscopic  or microscopic  adverse  effect  systemic  effects  and completed  bio‐
degradation  of D‐PLEX  by 6‐months.   
5.2.2 The safety  of D‐PLEX  administration  in the abdominal  wall incision  (muscle,  fat and 
subcutaneous)  was investigated  in rabbits  and swine.  D‐PLEX  had no local  or systemic  
adverse  effects  and did not impair  the healing  of the incision  nor increase  the 
adhesions  to the incisi on for about  [ADDRESS_1195030]‐administration.    
5.2.3 Two safety  studies  performed  to evaluate  the peritoneum  reaction  to D‐PLEX  after  24 
hours  and 28 days from  D‐PLEX  administration  in case of intra ‐abdominal  leakage  in rat 
abdominal  model  showed  that D‐PLEX  exposure  (comparable  on mg/kg  basis  to 15gr D‐
PLEX  in a 70‐kg adult)  to abdominal  cavity is safe.  
Hence,  D‐PLEX  can be considered  safe and suitable  for its intended  use.  
For detailed  non‐clinical  studies  summary  of the D‐PLEX,  see D‐PLEX  Investigators  Brochure,  
#DV‐0079.      
 
22-2-2022Page 31 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
5.3 CLINICAL  DATA  
A Phase  II, Prospective,  Multicenter,  Randomized,  Controlled,  Two‐arm,  Single  Blind   (Participant,  
Outcome  assessor)  Study  to assess  Safety  and Efficacy  of D‐PLEX  Administered  Concomitantly  
with SoC, compared  to a SoC treated  control  arm,  in prevention  of post abdominal  surgery  
incisional  infection  was performed  in [ADDRESS_1195031]  1 incision  that is g 5cm.  
The following  were  shown:   
 Proportion  of subjects,  who experienced  SSI or mortality  within  30 days:  10 subjects  on D‐
PLEX  + SoC as compared  to 24 subjects  on SoC treatment  arm (ITT population,  N=201)  met 
the Primary  Endpoint  (p‐value = 0.0086)  with SSI prevention  rate of 59%.  
 In the mITT  population  (N=185)  analysis,  9 subjects  on D‐PLEX  + SoC as compared  to 23 
subjects  on SoC treatment  arm met the Primary  Endpoint  (p‐value  = 0.0066)  with SSI 
prevention  rate of 61%.  
 In the PP population  analysis  (N=179)  7 subjects  on D‐PLEX  + SoC as compared  to 23 subjects  
on SoC treatment  arm met the Primary  Endpoi nt (p‐value  = 0.0024)  with SSI prevention  rate 
of 69%.  
 PK data (in 20 subjects)  demonstrat ed that the D‐PLEX  extended ‐release  formulation  re‐
leases  Doxycycline  constantly  over a period  of 30 days as well as that the systemic  exposure  
of D‐PLEX  is lower  than  any dose  of Doxycycline ‐based  product  administered  orally;  related  
to Cmax compared  to similar  PK variables  of the following  Reference  Listed  Products,  i.e., rela‐
tive, non‐head  to head  Cmax comparisons  to ACTICLATE,  VIBRAMYCIN  and DORYX  (labelling  
information  data)  and a medical  literature  citation18.  
 Three  (3) subjects  on SoC treatment  arm died during  the first [ADDRESS_1195032]‐surgery,  while  
none  on D‐PLEX  + SoC treatment  arm.  According  to PIs, these  cases  were  not related  to 
study  drug.  
 During  the Follow ‐up period  (60 days)  5 subjects  on SoC treatment  arm died ([ADDRESS_1195033]‐surgery).  According  to PIs, these  cases  were  not related  to study  
drug.  
 Total  Number  of Study  Drug ‐Related  Adverse  Events  (AEs)  as assessed  by [CONTACT_857761] 
8 TEAEs  reported  from  8 subjects  (N=99)  on D‐PLEX  + SoC versus  18 TEAEs  reported  from  13 
subjects  (N=100)  on SoC treatment  arm.  
 One (1) subje ct (N=101)  on D‐PLEX  + SoC and 8 subjects  (N=100)  on SoC treatment  arm 
discontinued  the study.  None  of them  discontinued  the study  due to AEs. 
     
 
22-2-2022Page 32 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
An additional  Phase  Ib/II clinical  trial in the Sternal  Surgical  Site indication  was conducted  in 
Israel  and included  two parts:  part 1, open  label  single  arm,  and part 2, randomized,  controlled,  
single ‐blinded  to assess  the safety  and efficacy  of D‐PLEX  concomitantly  with SoC vs. SoC alone,  
in the prevention  of sternal  wound  infection  post cardiac  surgery  for up to 24 weeks (6 months)  
following  surgery.  The study  included  a total  of 81 subjects  that were  scheduled  for open  heart  
surgery,  including  but not limited  to subjects  with high risk factors  for infection:  20 subjects  in 
part 1 (all in the treatment  arm)  and 61 subjects  in part 2 of the study  (21 subjec ts in the SoC 
arm and 40 subjects  in the treatment  arm).  
A total  of 60 subjects  were  randomized  to D‐PLEX  with SoC group.  One subject  withdrew  
consent  before  treatment.  
 
In a final Clinical  Study  report  for the study  the following  were  shown:  
 A single  subject  in the SoC group  (4.8%)  experienced  a superficial  surgical  wound  infection  
on Day [ADDRESS_1195034]‐surgery.  
 No subjects  in the treatment  group  experienced  any surgical  wound  infection  (0%).  
 No hospi[INVESTIGATOR_602],  re‐admissions  or surgical  re‐interventions  due to SSI were  reported  in 
the study.  
 No safety  issues  were  indicated,  and no AE/SAE  related  to D‐PLEX  has been  reported.  
18/21  subjects  in the SoC group  (85.7%)  and 48/60  subjects  (80%)  in the D‐PLEX  with SoC 
group  experienced  AEs. One subject  in the D‐PLEX  plus SoC group  died due to cardiogenic  
shock  on Day [ADDRESS_1195035]‐surgery,  not relate d to D‐PLEX  or the study  procedure.  
 PK data demonstrated  that D‐PLEX  releases  Doxycycline  continuously  over a period  of 30 
days as well as that the systemic  exposure  of D‐PLEX  is lower  than  any dose  of Doxycycline ‐
based  product  administered  orally;  related  to Cmax compared  to ACTICLATE,  VIBRAMYCIN  
and DORYX  (labelling  information  data)  and a medical  literature  citation18. 
These  results  are highly  clinically  meaningful  and statistically  significant,  and therefore  support  
the robustness  of D‐PLEX  in abdominal  SSI prevention.  In addition,  in this study  high safety  
profile  of the D‐PLEX  was shown.  
 
5.4 SAFETY  PROFILE  OF  DOXYCYCLINE  
Doxycycline  has been  on the market  for over 5 decades  and its side effects  are well established.  
Information  on adverse  reactions  of Doxycycline  capsules/  tablets  are provided  in the IB. 
Furthermore,  given  the total  dose  of Doxycycline  present  in D‐PLEX  (i.e., maximum  163.8mg),  
which  is lower  than  the overall  daily  dose  of systemically  administered  Doxycy cline  (200mg),  and 
given  it is being  gradually  released  over a period  of approximately  4 weeks,  it is unlikely  that     
 
22-2-2022Page 33 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
clinically  significant  systemic  levels  will be present  to give significant  side effects.  This is further  
supported  by [CONTACT_857762]  a phase  II clinical  study  which  was recently  
completed.  It shows  detectable  plasma  levels  of Doxycycline  for well into four weeks  following  
administration  of the D‐PLEX  formulation.  
5.5  POTENTIAL  BENEFITS  OF  D‐PLEX  FOR  PREVENTION  OF  POST  ABDOMINAL  
SURGERY  INCISIONAL  INFECTION  
● Prevention  of SSI, which  may occur  within  [ADDRESS_1195036]‐surgery.  
● Significant  improvement  in prevention  of SSI when  used  in surgical  procedures  that hold 
high risk of infection.  
● Induces  faster  recovery  and early  return  to normal  activity  as compared  to SoC due to lower  
SSI rate. 
● Reduction  in the number  of surgical  re‐interventions  due to surgical  site infections.  
● Reduction  in the number  of hospi[INVESTIGATOR_857710]/or  shortening  hospi[INVESTIGATOR_059],  thus 
providing  financial  savings  and reducing  hospi[INVESTIGATOR_857711]. 
● Used  concomitantly  with SoC. 
● Ease of administration,  no special  training  is required.  
● Local  administration  of effective  dose  of Doxycycline  during  surgery  (which  results  in local  
concentration  above  the MIC for Doxycycline  sensitive  bacteria),  which  cannot  be achieved  
by [CONTACT_857763].  
● Administration  of low total  dose  of Doxycycline  compared  to the dose  in oral administered  
Doxycycline  capsules.  
● Broad  spectrum  activity  of Doxycycline  (gram ‐negative  and gram ‐positive).  
● Low potential  risk for development  of bacterial  resistance.  
● D‐PLEX  excipi[INVESTIGATOR_857712],  widely  used  in the medicinal  or medical  device  
industry,  and have  an established  history  of safety  and clinical  use. 
● Reduced  risks of overall  toxicity  and adverse  side effects  due to minimization  of systemic  ex‐
posure.  
5.6 POTENTIAL  RISKS  OF  D‐PLEX  FOR  PREVENTION  OF  POST  ABDOMINAL  SURGERY  
INCISIONAL  INFECTIONS  AND  THEIR  MITIGATIONS  
Potential  contamination  of microorganisms  and pyrogens  by [CONTACT_857764].  
Mitigation:  
 Clear  and detailed  instructions  on how to store,  administer  and use.     
 
22-2-2022Page 34 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195037]  level:  
 In case of serious  local  toxicity  induced  by D‐PLEX,  removal  and washing  out the product  
will be done  by [CONTACT_857765].  
Mitigations  at the population  level:  
 Close  follow  up of subjects  
 Safety  Monitoring  
Hypersensitivity  to Doxycycline  and to the Tetracycline  family  of antibiotics  
Mitigation:  
 Exclude  susceptible  subjects  with known  allergy  to Doxycycline  / Tetracycline  family  and/or  
three  different  allergens.  
 In case of allergic  reaction  to Doxycycline,  the administered  D‐PLEX  can be removed  by [INVESTIGATOR_1312]‐
exploring  the surgical  target  incision  and washing  out the D‐PLEX. 
Potential  of bacteria  resistant  to Doxycycline ‐treatment  failure/  increased  severity  of infection.  
Mitigation:  
 SoC concomitantly  administered  with D‐PLEX  provides  systemic  antibacterial  coverage.  
Administration  outside  of the target  surgery  site. 
Mitigations:  
 Training  of the surgeons  participating  in the clinical  trials,  as part of the study  initiation  and 
the protocol  training.  
 Clear  instructions  how to apply,  detailed  in section  0.    
Inadequate  antibacterial  activity  of the product  
Mitigations:  
 SoC concomitantly  administered  with D‐PLEX  provides  systemic  antibacterial  coverage.  
Re‐use of D‐PLEX  between  different  subjects,  can lead to cross  contamination.  
Mitigations:  
 D‐PLEX  vial will be re‐allocated  to a different  subject  only if (i) package  carton  was never  
opened  (ii) storage  conditions  were  kept and (iii) with the permission  of the site’s  head  of 
pharmacy.  If, for some  reason,  it was not used  also after  the 2nd allocation  ‐ any remaining  
drug  not applied  should  be discarded.  
 Training  of site clinical  staff.  
Photosensitivity  reaction:  exaggerated  sun burn reaction.  
Mitigations:  
 Close  follow  up of subjects  
Transient  hypercalcemia  
     
 
22-2-2022Page 35 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
Mitigation:  
 Close  follow  up of subjects.  
Blood  levels  of calcium  are tested  at screening  and every  visit after  the procedure  during  the 
clinical  study.  
5.6.1 Potential  Risks  and Mitigations  due to COVID ‐19 pandemic   
Potential  risks due to COVID ‐19 pandemic  were  evaluated  according  to Guidance  on the 
management  of clinical  trials  during  the Covid ‐19 (coronavirus  pandemic)risks  and 
mitigations  are presented  below  in the table  below.  
Risk   Mitigation  
1. Subject  may be infected  
with SARS ‐2‐COV prior  to 
enrollment  to the study  Charlson  Patient  characterization:  the updated  Charlson  co‐morbidity  index  
(CCI)  that include  question  Is this a COVID ‐19 patient?  is used  (see Appen ‐
dix 5). 
2. Subject  was diagnosed  to 
be infected  with SARS ‐2‐
COV and must  undergo  ab‐
dominal  surgery    Hospi[INVESTIGATOR_857713] ‐19 patients  as 
needed.   
 D‐PLEX  is a new formulation  of extended  release  of Doxycycline  to be 
administered  locally  as a single  application  during  abdominal  surgeries.  
Systemic  exposure  of Doxycycline  from  D‐PLEX  is lower  than any dose  
of Doxycycline ‐based  product  administered  orally.  Therefore,  no poten ‐
tial interaction  is expected  with any additional  medications  as needed  
in this situation.  
3. Subject  treatment  can be 
interrupted  due to arriv‐
ing/visits  issues  As D‐PLEX  is administered  locally  as a single  application,  there  is no risk to 
interrupt  the continuing  treatment  due to COVID ‐19 pandemic  situation.  
4. Study  Follow ‐up visits  cant  
be performed  on site due 
to COVID ‐19 pandemic  sit‐
uation  and safety  of the 
subject  can be compro ‐
mised   During  the study,  4 of 7 visits  are conducted  during  the primary  hospi ‐
talization  for the abdominal  surgery.  The additional  3 visits  can be done 
by [CONTACT_648].   
 According  to Table 1, in case the subject  is unable  to attend  a visit,  in‐
formation  related  to his wound  assessment  (as per Sponsors  desig ‐
nated  form)  should  be obtained  in a phone  conversation  with him/his  
community  physician/  a first degree  relative.   
 During  remote  visit,  the patie nt will be asked  to photocop y the incision  
area only,  using  their  cellular  phone  per instructions  provided  as a sep‐
arate  manual  to help the investigator  and independent  and blinded  ad‐
judication  committee  to perform  wound  assessment  (see Section  
9.1.18).  
 In case Central  laboratory  cant  be used  due to COVID ‐19 pandemic  
(home  visits  and/or  connec tion disturbances),  Local  laboratories  can be 
used  to assess  the safety  and efficacy  (bacteriology  test) of the subject.      
 
22-2-2022Page 36 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
5.7 SAFETY  & EFFICACY  SUMMARY  
Based  on the current  data available  from  2 clinical  studies  with D‐PLEX,  in which  99 subjects,  
who underwent  abdominal  surgery,  and 58 cardiac  subjects  were  treated  with D‐PLEX,  no safety  
concern  was observed.  Overall,  based  on risk/benefit  assessment,  the expected  benefits  
outweigh  the expected  risks associated  with the use of D‐PLEX.  
Therefore,  a clinical  trial with D‐PLEX  in subjects  undergoing  abdominal  surgery  procedures,  may 
be beneficial.  
6 OBJECTIVES  
● To assess  the anti‐infective  efficacy  of D‐PLEX  (administered  concomitantly  with SoC) over a 
period  of [ADDRESS_1195038] operation,  by [CONTACT_857766]/or  deep  
abdominal  wall surgical  incision  infection,  compared  to the SoC treatment  control  arm.  
● To assess  the safety  of D‐PLEX.  
 
7 STUDY  ENDPOINTS  
7.1 PRIMARY  EFFICACY  ENDPOINT  
The following  will be evaluated  in this trial: 
Infection  rate as measured  by [CONTACT_857767],  occurring  within  
[ADDRESS_1195039] abdominal  surgery  and determined  by a blinded  and independent  adjudication  
committee.  
The blinded  and independent  adjudication  committee  review  will include  all index  surgery  
incisions,  regardless  of any re‐intervention  at the target  site (i.e. re‐opening  of the surgery  
incision,  used  for the original  index  surgery),  for the determination  of infection  status.  The 
committee  will also assess  re‐interventions  at the primary  incision  site throug h the abdominal  
incision  (target)  for the determination  of re‐intervention  due to suspected  SSI or due to poor  
wound  healing,  including  wound  dehiscence.  Such  event  as well as  all‐cause  mortality  within  [ADDRESS_1195040] index  surgery  will be analysed  as treatment  failure.   
 
Reinterventions  for other  reasons  likely  unrelate d to the initial  treatment  (as determined  by 
[CONTACT_857768];  e.g. anastomosis  leaks,  intraabdominal  
hemorrhage,  bowel  obstruction),  will be not  be considered  as failures  in the primary  analysis  
of the primary  endpoint.  
Reintervention  is defined  as re‐opening  of the surgery  incision,  used  for the original  index  
surgery,  in the operation  room  (OR).  
 
SSI is defined  as Deep  Incisional  Surgical  Site Infection  (DSSI)  and/or  Superficial  Incisional  Surgical  
Site Infection  (SSSI).      
 
22-2-2022Page 37 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
 
Superficial  incisional  SSI ‐ Infection  involves  only skin and subcutaneous  tissue  of the incision  
and does  not include  diagnosis/treatment  of cellulitis,  a stitch  
abscess  alone  or a localized  stab wound  or pin site infection.  
Deep  incisional  SSI ‐  Infection  involves  deep  tissues,  such  as fascia  and muscle  layers;  this 
also includes  infection  involving  both  superficial  and deep  incision  
sites.    
An organ/space  SSI (e.g.,  infection/abscess  in the operated  organ  or peritoneal  cavity)  will not be 
accounted  as an endpoint  event.  
Identification  of  an SSI  will  be  based  on  CDC/NHSN  Patient  Safety  Component  Manual  criteria  
(January  2020,  chapter  9). 
 
7.2 SECONDARY  EFFICACY  ENDPOINTS  
7.2.1 Key  endpoints:  
● Infection  rate as measured  by [CONTACT_857769],  occurring  within  [ADDRESS_1195041] abdominal  surgery  and 
determined  by a blinded  and independent  adjudication  committee.  
[abdominal  incisional  infection  is defined  as Deep  Incisional  Surgical  Site Infection  (DSSI)  
and/or  Superficial  Incisional  Surgi cal Site Infection  (SSSI)].  
● Number  (percent)  of subjects  with at least  1 score  of ASEPSIS  > [ADDRESS_1195042] 
abdominal  surgery.  
7.2.2 Additional  endpoints:  
● Incidence  of SSSI during  [ADDRESS_1195043] index  surgery.  
● Incidence  of DSSI during  [ADDRESS_1195044] index  surgery.  
● All‐cause  mortality  rate within  [ADDRESS_1195045] randomization.  
● All‐cause  mortality  rate within  [ADDRESS_1195046] randomization.  
● Time  to adjudicated  target  incisional  SSI post‐surgery  during  [ADDRESS_1195047] index  surgery.    
● Number  (percent)  of subjects,  re‐admitted  during  [ADDRESS_1195048]‐surgery  (for any reason)  and 
experienced  adjudicated  SSI during  this re‐admission.  
● Number  (percent)  of subjects  who experienced  at least  1 surgical  re‐intervention  due to 
adjudicated  SSI during  [ADDRESS_1195049]‐surgery.  Re‐intervention  is defined  as re‐opening  of the 
surgery  incision,  used  for the original  index  surgery,  in the operation  room  (OR) 
[IP_ADDRESS]  SSI  related  Additional  Endpoints:  
● Number  (percent)  of subjects  with adjudicated  SSI where  at least  one Doxycycline ‐re‐
sistant  bacteria  has grown  during  the bacteriology  tests.       
 
22-2-2022Page 38 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
● Number  (percent)  of Doxycycline ‐resistant  bacteria  out of all bacteria  that were  grown  
during  the bacteriological  tests  from  subjects  with adjudicated  SSI.  
● Number  (percent)  of subjects  who experienced  adjudicated  SSI during  [ADDRESS_1195050]‐
surgery  that was treated  by [CONTACT_857770].  
● Number  of IV antibiotic  treatment  days administered  to subjects  experienced  adjudicated  
abdominal  incisional  SSI during  [ADDRESS_1195051]‐surgery.  
● Average  of subjects  cumulative  ASEPSIS  assessment  score  (AUC)  for subjects  with 
adjudicated  SSI during  [ADDRESS_1195052]‐surgery.  
● Number  (percent)  of subjects  with at least  1 score  of ASEPSIS  > [ADDRESS_1195053] abdominal  index  surgery.  
 
7.3 SAFETY  EVALUATION  
The following  safety  parameters  will be evaluated  in this trial:  
 AEs, physical  examinations  & vital signs.  
 Incisional  wound  healing  (including  Hernia)  will be assessed  by a blinded  Investigator,  
using  a visual  examination  (part  of a Surgical  Site Assessment  questionnaire)  as well as 
Modified  Vancouver  Scar  Scale  wound  assessment  questionnaires.  
 Safety  labora tory parameters:  hematology,  chemistr y. 
8 TRIAL  DESIGN  
8.1  OVERALL  DESIGN  
This is a phase  III, prospective,  multinational,  multicenter,  randomized,  controlled,  two‐arm,  
double  blind  study.  The study  population  includes  male  and female  subjects,  [ADDRESS_1195054]  1 abdominal  target  incision  that is > [ADDRESS_1195055]  the demographic  for clinically  relevant  population  with regards  to: 
age, gender,  race and ethnicity.  This population  reflect  the US and Europe  population  undergoing  
abdominal  colorectal  surgeries.  Subjects  who meet  the inclusion  criteria  and none  of the exclusion  
criteria  and who provide  a signed  Infor med Consent  Form  will be enrolled  in the study.  
Subjects  will be randomized  to either  the investigational  arm (SoC + D‐PLEX)  or to the control  arm 
(SoC only)  in a 1:1 ratio.  Subjects  will be stratified  by [CONTACT_857771]  
(prophylactic  IV antibiotics  with mechanical  bowel  preparation  or prophylactic  IV antibiotics  
without  mechanical  bowel  preparation)  and by [CONTACT_11338]  (US or Europe  + Israel).  
The sponsor,  the outcome  assessor,  the subjects  and all staff involved  in the collection  and 
recording  of the clinical  and laboratory  data,  based  on which  the independent  adjudication      
 
22-2-2022Page 39 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
committee  will perform  their  assessment,  will be blinded  to the treatment  assignment.  The 
OR staff will be trained  to maintain  in confident  the treatment  assignment  and not to disclose  
it to other  staff members.  In addition,  all aspects  of data management  and clean ‐up should  be 
done  using  blinded  datasets.  For subje cts randomized  to the investigat ional  arm,  D‐PLEX  
treatment  will be applied  during  the abdominal  surgery  at the stage  of closure  of the 
abdominal  wall surgical  target  incision  (index  procedure),  as an adjunct  to the SoC treatment  
per protocol.   
D‐PLEX  will not be re‐administered  if any reintervention  occurs.  Reintervention  is defined  as 
re‐opening  of the surgery  incision,  used  for the original  index  surgery,  in the operation  room  
(OR).   
For subjects  randomized  to the control  arm,  the surgical  treatment  will be as per SoC treatment.  
SoC will be consistent  and standardized  for all sites in the study  and is composed  of IV antibiotic  
immediately  prior  to surgery.  Each  site will use the same  pre‐defined  SoC for all its subjects  during  
the study.  
For subjects  from  both  arms,  preoperative  IV antibiotics  will be composed  of 1st or 2nd generation  
of Cephalosporin  family  plus Metronidazole  given  within  60 minutes  prior  to surgery  and should  
be discontinued  maximum  24‐hour  post‐surgery.  In case of allergy  to the Cephalosporin,  Penicillin  
families  or Metronidazole,  other  IV antibiotic  may be used.   Pre‐operation  prophylacti c oral 
antibiotic  is not allowed.   Mechanical  bowel  preparation  will be at the discretion  of the PI [INVESTIGATOR_857714]’s  SOP.  Post‐operative  resumption  of activity  is at the discretion  of the Investigator  based  on 
the subject’s  medical  condition.  
Doxycycline  pharmacokinetic  sampling  will be collected  in selected  sites from  all randomized  
subjects  in these sites (sites  from  Czech  Republic  will not participate  in the PK sub‐study).  About  
 series  of samples  per set will be analyzed.  About  series  will be analyzed  from  subjects  
receiving  2 vials,  about  series  will be analyzed  from  subjects  receiving  3 vials.   
The occurrenc e of any Adverse  Events  (AE/SAE)  including  death  will be recorded  throughout  the 
study.  
The planned  clinical  study  will evaluate  the efficacy  of D‐PLEX  in the prevention  of SSIs over a 
period  of 30 days for the primary  outcome.  All subjects  will be followed  for an overall  of 60 days 
for safety.  
8.2 DESCRIPTION  & JUSTIFICATION  OF  THE  DURATION  OF  TREATMENT,  SUBJECT  
PARTICIPATION  AND  TRIAL  FOLLOW ‐UP  
The infection  rate is measured  within  [ADDRESS_1195056]  of the abdominal  surgery  surgical  wound  infections  occur  3,14,15.     
 
22-2-2022Page 40 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
The 60 days follow ‐up period  was determined  to allow  a sufficient  follow ‐up period  to 
demonstrate  the initial  and sustainability  safety  endpoints  of D‐PLEX.  
8.3 SELECTION  OF  SUBJECTS  
The study  will enrol  a minimum  of 950 subjects,  with 475 subjects  allocated  to each  treatment  group.   
The final number  of subjects  will be determined  following  an unblinded  sample  size re‐estimation:  
when  about  750 subjects  will complete  their  30 days (1 month)  follow ‐up and evaluated  for primary  
endpoint.  See details  in the section  14.3.8.    
8.[ADDRESS_1195057]  meet  all of the following  criteria:  
1. Subjects  undergoing  an elective  colorectal  surgery  involving  resection,  with or without  a 
stoma  formation,  that includes  at least  1 abdominal  incision  that is > 10cm  (target  incision).   
2. Subjects  are preoperative  hemodynamically  stable  (BPf180/110  and 90/60  mmHg,  and 
HRf100 and 60 bpm,  and temperature  f38.50C and 35.50C). 
3. Male  or non‐pregnant  female.  
4. Female  of child ‐bearing  potential  should  have  a negative  pregnancy  test (serum  or urine  
dipstick)  prior  to index  procedure.  Note:  All  female  subjects  of child ‐bearing  potential  must  
agree  to  use  a highly  effective  method  of contraception  consistently  and  correctly  for  the  
duration  of the  study  (see  Section  8.6   CONTRACEPTIVE  METHODS).  
5. Subjects  age [ADDRESS_1195058]  safety.  
Therefore,  adherence  to the criteria  as specified  in the protocol  is essential.  
Subjects  who meet  any of the exclusion  criteria  are prohibited  from  participating  in the study:  
1. Subjects  with suspected/diagnosed  intestinal  perforation,  intra ‐abdominal  abscess,  or any     
 
22-2-2022Page 41 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
emergency/urgent  colorectal  surgery  with acute  intestinal  obstruction  (ex. toxic  colitis,  
ileus/sub ‐ileus,  megacolon,  diverticulitis,  volvulus,  ect.)  
2. Subjects  who underwent  an intra ‐abdominal  surgery  within  the last [ADDRESS_1195059] one week  prior  to randomization,  excluding  pre‐operative  prophylaxis  or antibiotics  for 
the treatment  of the disease  that is the indication  for surgery.  
4. Subjects  undergoing  concomitant  major  procedures  in addition  to the abdominal  surgery,  
including  concomitant  repair  of ventral  hernia.  Salpi[INVESTIGATOR_8936] ‐oophorectomy  and cholecystectomy  
are allowed.   
5. Subjects  who received  any anti‐cancer  treatment  within  the last 4 weeks  of surgery.  
6. Subjects  who received  radiation  for colorectal  cancer  to the abdomen  area,  prior  to the 
planned  abdominal  surgery.  
7. Subjects  who received  oral or IV Doxycycline/Tetracycline  family  antibiotic  during  the past 4 
weeks  prior  to randomization.  
8. Subjects  with known  allergy  to Doxycy cline  and/or  to the tetrac ycline  family  of drugs  or to 
the D‐PLEX’s  excipi[INVESTIGATOR_840].  
9. Subjects  with known  allergies  to more  than  3 substances  (an allergy  questionnaire  will be 
completed  during  the screening  process).  
10. Subjects  with history  of severe  allergic  reaction  to any substance,  having  required  treatment  
with intravenous  steroids/intramuscular  epi[INVESTIGATOR_22493] e, or who in the opi[INVESTIGATOR_857715].  
11. Subjects  with End Stage  Renal  Disease  (ESRD/CKD  stage  5). 
12. Subjects  with severe  hepatic  impairment.  
13. Subjects  with chronic  urticaria.  
14. Subjects  diagnosed  with CVA within  the past 6 months  prior  to randomization.  
15. Subjects  that undergone  any abdominal  surgery  and current  plann ed index  surgery  involves  
re‐opening  the scar of a prior  abdominal  surgery  performed  within  the last [ADDRESS_1195060]  with an active  malignancy,  other  than resectable  non‐metastatic  colorectal  
cancer,  that is the reason  for the index  surgery, or carcinoma  in situ (or other  cancer  "in situ 
= Stage  0"), or squamous  cell carcinoma  of the skin or basal  cell carcinoma  of the skin;  or a 
malignancy  that has not been  in complete  clinical  remission  and without  maintenance  chemo  
or immunotherapy  for at least  3 years.   
17. Subjects  with other  concurrent  severe  and/or  uncontrolled  medical  condition.      
 
22-2-2022Page 42 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195061] ‐feeding  women  or women  of child ‐bearing  age who refuse  or are 
prohibited  of using  an effective  contraceptive  method  of birth control  throughout  study  
participation,  including  the safety  follow ‐up period.  
21. Subjects  who received  any investigational  drug  within  30 days or 5 half‐lives prior  to 
randomization  to the study  (whichever  is longer)  and through  the study.  
22. Subjects  participating  in any other  interventional  studies.  
23. Subjects,  who in the opi[INVESTIGATOR_857696],  are not eligible  to participate  in the study  
and/or  to comply  with protocol  requirements  (e.g.,  due to a cognitive  or medical  condition).  
8.6 CONTRACEPTIVE  METHODS  
Women  of child  bearing  potential  (WOCBP),  will only be included  in the study  after  confirmed  
menstrual  period  and a negative  serum/dipstick  pregnancy  test. Women  of childbearing  
potential  (WOCBP)  is defined  as any woman  or adolescent  who has begun  menstruation.  A post‐
menopausal  woman  is defined  as a woman  who is over the age of [ADDRESS_1195062] for 
the duration  of the study  (until  visit 7  Day 60): 
 Combined  (estrogen ‐ and progestogen ‐ containing)  hormonal  contraception  asso‐
ciated  with inhibition  of ovulation1 (oral,  intravaginal,  transdermal)  
 Progestogen ‐only hormonal  contraception  associated  with inhibition  of ovulation1 
(oral,  injectable,  implantable2) 
 Intrauterine  device  (IUD)2 
 Intrauterine  hormone ‐releasing  system  (IUS)2  
 Bilateral  tubal  occlusion2 
 Vasectomised  partner  2,3 
 Sexual  abstinence4 
[ADDRESS_1195063]  low user 
dependency.  
3 Vasectomised  partner  is a highly  effective  contraception  method  provided  that the partner  is 
the sole sexual  partner  of the WOCBP  trial participant  and that the vasectomised  partner  has 
received  medical  assessment  of the surgical  success.      
 
22-2-2022Page 43 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195064].  
    
Note : The following  are not acceptable  methods  of contraception:  
 Periodic  abstinence  (calendar,  symptothermal,  post‐ovulation  methods),  withdrawal  (coi‐
tus interruptus),  spermicides  only,  and lactational  amenorrhea  method  (LAM).  
 Male  condom  with cap, diaphragm,  or sponge  with spermicide.  
 Male  and female  condom  should  not be used  together  (due to risk of failure  with friction).     
8.[ADDRESS_1195065]  recruitment  will be conducted  in general  surgery  departments  at sites in US, Europe  & Israel.  
Recruitment  period  is expected  to take approximately  12 months.  
9 STUDY  PROCEDURES  & SCHEDULE  OF  ASSESSMENTS  
9.1 STUDY  PROCEDURES   
9.1.1 Informed  Consent  Procedure  
An Informed  Consent  Form  (ICF) will be prepared  in accordance  with the study  protocol,  ICH 
GCP and any applicable  global  and national  regulations/requirements.  The consent  will include  
the information  that data will be recorded,  collected,  processed,  and may be transferred  to 
Competent  Authorities.  In accordance  with the applicable  global  and national  regulations,  the 
data will not identify any subjects  taking  part in the study.  
The final EC/IRB  approved  ICF and a copy  of the approval  must  be submitted  to the Sponsor  
prior  to the initiation  of subject  enrolment  at each  investigational  site. 
Prior  to any study ‐specific  procedure  or assessment,  all subjects  must  document  their  consent,  
in writing,  for study  participation  and authorization  for use and disclosure  of health  
information  by [CONTACT_857772]. As part of the consent  process,  the subject  will have  the 
opportunity  to ask questions  and receive  answers  from  the personnel  conducting  the study  
and will have  ample  time to consider  and consul t prior  to providing  consent  to participate  in 
the study.    
An original  signed  copy  of the ICF will be retained  at the investigational  site and a copy  of the 
signed  consent  form  will be provided  to the subject.  
Procedures  conducted  as part of the subjects  routine  clinical  management  (e.g.,  imaging)  and 
obtained  prior  to signing  of the ICF may be used  for screening  or baseline  purposes  provided  
the procedure  meets  the protocol ‐defined  criteria  and has been  performed  within  the 
timeframe  specified  in the protocol.      
 
22-2-2022Page 44 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195066]s  future  health  and medical  care,  such information  shall be provided  to the respective  
affected  subject  in writing.   If relevant,  all affected  subjects  shall be asked  to confirm  their  
continuing  informed  consent  in writing.    
 
9.1.2 Screen  Failure  
Subjects  who sign the ICF, but do not meet  the eligibility  criteria  and were  not randomized  will 
be considered  as screen  failures.  
For such  subjects,  the reason  for screen  failure  will be recorded  in the screening  log, the Case  
Report  Form  (CRF)  and in the source  documents.  
 
9.1.3 Randomization  / Enrolment  
Upon  confir mation  that the subject  fulfils  all inclusion  criteria  and none  of the exclusion  
criteria  are met,  he/she  will be randomized  through  an interactive  web randomization  system  
(IWRS)  integrated  with the eCRF,  based  on subjects  information  collected  during  the 
screening  period  and details  of the planned  index  surgery.  
Randomization  will be done centrally  using  a randomization  specification  prepared  by [CONTACT_857773]  (not involved  to the study),  
which  will assign  subjects  in a 1:1 ratio  to: 
● Investigational  Arm  Standard  of Care (SoC)  concurrently  with D‐PLEX  application.  
● Control  Arm  SoC treatment  alone.  
Randomization  will be stratified  by [CONTACT_857771]  
(prophylactic  IV antibiotic  with mechanical  bowel  preparation  or prophylactic  IV antibiotic  
without  mechanical  bowel  preparation)  and by [CONTACT_11338]  (US or Europe  + Israel).   
Instructions  and training  for randomization  and stratification  process  will be provided  
during  the site initiation  visit. 
9.1.4 Blinding  
This is a double  blind  clinical  trial.  The sponsor,  the subjects,  outcomes  assessor  and all staff 
involved  in the collection  and recording  of the clinical  and laboratory  data,  based  on which  the 
independent  adjudication  committee  will perform  their  assessment,  will be blinded  to 
treatment  assignment.  In addition,  all aspects  of data manage ment  and clean ‐up will be done  
in blinded  datasets.      
 
22-2-2022Page 45 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
The study  site personnel,  who perform  the index  surgery  or re‐intervention  procedure  (OR 
staff),  will be trained  not to disclose  the treatment  arm to the blinded  Investigator,  or other  
staff members,  the subject(s),  his/her  family,  to other  health  care providers  not present  during  
the surgery  or to the study  Sponsor  representatives . 
When  relevant,  unblinded  information  (e.g.,  surgery  report)  will be reviewed  by [CONTACT_857774],  prior  to filing  of 
the relevant  document  to the patient  study  file. 
Wound  assessment,  AE assessment  and other  study  outcomes  throughout  the study  follow ‐up 
visits  will be done  by a blinded  Investigator,  who will not be involved  in the surgery.  
All blinded  /unblinded  activities  are described  in each  sites  blinding  plan.  
An emergency  card containing  the Study  Name,  NIH number,  Center  Name/number,  PIs name 
[CONTACT_271786]  [CONTACT_857775]. Subjects  will be instructed  to keep  this 
card with them  at all times  and present  it to medical  staff in case of a medical  urgency.  
 
9.1.[ADDRESS_1195067]  one Investigator  (treating  surgeon)  that is unblinded  to the study  
treatment.  In occasion  this person  is unavailable  and unblinding  is deemed  necessary  and 
emergent,  unblindin g could  be done  by [CONTACT_857776]  (24/7  support  
via phone  call).   
In general,  the actual  allocation  will be not disclosure  to the subject.  In case it will be 
necessary  for the subjects  safety,  the Investigator  will disclose  the actual  treatment  
information  to the said subject.  
The Investiga tor is requested  to maintain  the blindin g as much  as possible.  Investigators  are 
encouraged  to discuss  unblinding  in advance  with a Sponsor’s  representative  if he/she  believes  
that unblinding  is necessary.  The actual  treatment  allocation  must  NOT be disclosed  to the 
subject  and/ or other  blinded  study  personnel  including  blinded  site personne l, monitors,  
corporate  Sponsors  or project  office  staff.  
The Investigator  must  report  all code  breaks  (with  reason)  as they occur  to the study  monitor.  
 
 
 
     
 
22-2-2022Page 46 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195068] abdominal  surgery.  All‐
cause  mortality  within  [ADDRESS_1195069] index  surgery,  will be analysed  as treatment  failure.  The 
blinded  and independent  adjudication  committee  review  will include all index  surgery  
incisions,  regardless  of any re‐intervention  at the target  site (i.e. re‐opening  of the surgery  
incision,  used  for the original  index  surgery),  for the determination  of infection  status.  
SSI is composed  of Deep  SSI and/or  Superficial  SSI. 
Superficial  incisional  SSI ‐   Infection  involves  only skin and subcutaneous  tissue  of the 
incision  and does  not include  diagnosis/treatment  of cellulitis,  a 
stitch  abscess  alone  or a localized  stab wound  or pin site infection.  
Deep  incisional  SSI ‐   Infection  involves  deep  tissues,  such  as fascia  and muscle  layers;  
this also includes  infection  involving  both  superficial  and deep  
incision  sites.  
An organ/space  SSI (e.g. infection/abscess  in the operated  organ  or peritoneal  cavity)  is 
excluded  and will not be accounted  as an endpoint  event.  
SSI  will  be  identified  by  [CONTACT_857777]/NHSN  Patient  Safety  Component  
Manual  (January  2020,  chapter  9).  
Superficial  Incisional  SSI must  meet  the following  criteria:  
Date  of event  for infection  occurs  within  30 days after  any NHSN  operative  procedure  (where  
Day 1 = the procedure  date)  
       AND 
  Involves  only skin and subcutaneous  tissue  of the incision  
 AND 
  Patient  has at least  one of the following:  
a)  Purulent  drainage  from  the superficial  incision  
b)  Organisms  identified  from  an aseptically ‐obtained  specimen  from  the superficial  
incision  or subcutaneous  tissue  by a culture  or non‐culture  based  microbiologic  testing  
method  which  is performed  for purposes  of clinical  diagnosis  or treatment  (for example,  
not Active  Surveillance  Culture/Testing  (ASC/AST)).  
c) Superficial  incision  that is deliberately  opened  by a surgeon,  physician  or physician  
designee  and culture  or non‐culture  based  testing  of the superficial  incision  or 
subcutan eous  tissue  is not performed  
        AND     
 
22-2-2022Page 47 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195070]  one of the following  signs  or symptoms:  (1)  localized  pain or 
tenderness,  (2)  localized  swelling,  (3) erythema  or (4)  heat.    
d) Diagnosis  of a Superficial  Incisional  SSI by [CONTACT_857778].  
*The  following  do  not  qualify  as  criteria  for  meeting  the  NHSN  definition  of superficial  incisional  
SSI:  
 Diagnosis/treatment  of cellulitis  (redness/warmth/swelling),  by  [CONTACT_5071],  does  not  meet  criterion  
for  superficial  incisional  SSI.  Conversely,  an  incision  that  is draining  or  that  has  organisms  
identified  by  [CONTACT_857779] ‐culture  based  testing  is not  considered  a cellulitis.  
 A stitch  abscess  alone  (minimal  inflammation  and  discharge  confined  to the  points  of suture  
penetration).  
 A localized  stab  wound  or  pin  site  infection  is not  considered  an  SSI;  depending  on  the  depth,  
these  infections  might  be  considered  either  a skin  (SKIN)  or  soft  tissue  (ST)  infection.  
Deep  Incisional  SSI must  meet  the following  criteria:  
The date of event  for infection  occurs  within  30 days after  the operative  procedure  (where  
Day 1 = the procedure  date)  
       AND 
Involves  deep  soft tissues  of the incision  (e.g.,  fascia  and muscle  layers)  
        AND 
Patient  has at least  one of the followings:  
a)     Purulent  drainage  from  the deep  incision.    
b)     A deep  incision  that spontaneously  dehisces,  or is deliberately  opened  or aspi[INVESTIGATOR_857716] 
a physician  and organism  is identified  from  the deep  soft tissues  of the incision  by a culture  
or non‐culture  based  microbiologic  testing  method  which  is performed  for purposes  of 
clinical  diagnosis  or treatment  (for example,  not Active  Surveillance  Culture/Testing  
(ASC/AST))  or culture  or non‐culture  based  microbiologic  testing  method  is not performed.  
A culture  or non‐culture  based  test from  the deep  soft tissues  of the incision  that has a 
negative  finding does  not meet  this criterion.  
                AND 
               Patient  has at least  one of the following  signs  or symptoms:  (1) fever  (>38°C);  (2) 
localized  pain or (3) tenderness.  
  c)     An abscess  or other  evidence  of infection  involving  the deep  incision  that is detected         
on gross  anatomical  or histopathologic  exam,  or imaging  test. 
     
 
22-2-2022Page 48 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
9.1.9 Adverse  Events  
The Investigator  and site staff are responsible  for detecting,  documenting,  and reporting  
events  that meet  the definition  of an AE.  
AEs will be collected  from  randomization,  throughout  the study,  and until study  termination  at 
visit 7 (60 days after  surgery).   AEs suspected  to be related  to the IP should  be followed  up 
until resolution  or permanent  outcome.  
Details  on AE detecting,  docume nting,  and reporting  can be found  in section  10. 
 
The study  sponsors  medical  representative  will review  and assess  SAEs  and  AEs suspected  to 
be related  to investigational  medicinal  product.  
The sponsor  will adjudicate  if a safety  report  meet  the definition  of S[LOCATION_003]R,  based  on the 
applicable  regulations.  Details  on S[LOCATION_003]R  reporting  can be found  in section  10.10  REPORTINGS  
OF S[LOCATION_003]Rs.     
In case of dispute  between  the Investigator  and the sponsor,  the more  severe  assessment  will 
prevail.  
SSI will be handled  as AEs and will be followed  by [CONTACT_149870]s  applicable  sections  for AE 
collection  and reporting.  Symptoms  of SSI that do not meet  an SSI diagnosis  will be reported  as 
AEs. 
Pregnancy  will be reported  using  a specific  form  and will be followed  up until resolution.  
The Data  Monitoring  Committee  (DMC)  will review  all study  safety  data periodically  until last 
subject  last visit and provide  its recommendation  to the Sponsor  if study  may continue  based  
on subjects’  safety  and any other  ethical  consideration  as applicable.   
Details  on AE definition,  assessment  and reporting  can be found  in section  10.5 RECORDING  
& REPORTING  OF ADVERSE  EVENTS  & REACTIONS.    
 
9.1.10  Laboratory  Examinations  
All protocol ‐required  laboratory  assessments  must  be conducted  in accordance  with the 
Central  Laboratory  Manual  and Protocol  Time  and Events  Schedule.  
If any local  laboratory  assessments  are performed  during  the course  of the trial and they result  
in a change  in subject  management  (for example  due to a S/AE)  the assessment  data must  be 
recorded  in the subjects  eCRF.  
9.1.11  Central  Laboratory  
Complete  clinical  chemistry  and hematology  samples  will be collected  and shipped  to the ICON 
Central  Laboratory.   
 
     
 
22-2-2022Page 50 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195071]  number,  protocol  number,  site/ center  number,  and visit date.  Details  regarding  
the preparation  and shipment  of samples,  and a list of reference  ranges  for all safety  
parameters  will be provided  by [CONTACT_857780] .   
Clinical  Chemi stry  Parameters  
Albumin  
Alkaline  Phosphatase  
Alanine  Transaminase  (ALT)  
Aspartate  Aminotransferase  (AST)  
Blood  Urea  Nitrogen  (BUN)  
Calcium  
Chloride  
Creatinine  
C‐Reactive  Protein  (CRP)  
Glucose  
Lactate  Dehydrogenase  (LDH)  
Phosphate  
Potassium  
Sodium  
Total  Bilirubin  
Total  Protein  
Creatinine  Phosphokinase  (CPK)  
Hematology  Parameters  
Red Blood  Cell (RBC)  Count  
Hemoglobin  (HGB)  
Hematocrit  (HCT)  
Platelet  Count  
White  Blood  Cell (WBC)  Count  
WBC  Differential  (expressed  as % and as absolute):  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils      
 
22-2-2022Page 51 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
9.1.12  Local  Laboratory  
Accreditations  and reference  range  will be collected  for all local  laboratories  and thereafter  
defined  in the eCRF.  
The following  laboratory  tests  will be performed  and analysed  at the Screening  visit and for 
baseline  status  only.   
 
Coagulation  Parameters   to be done  at Screening  visit 
Prothrombin  Time  (PT) 
Activated  Partial  Thromboplastin  Time  (aPTT)  
International  Normalized  Ratio  (INR)  
Urinalysis   to be done  at Screening  visit and as per Investigator  discretion  
pH 
Specific  Gravity  
Protein  
Glucose  
Bilirubin  
Ketones  
Nitrites  
Leukocytes  
Erythrocytes  
Pregnancy  test (β‐HCG)  by [CONTACT_857781],  will be performed  in 
female  subjects  of child ‐bearing  potential  only.   
Any abnormal  laboratory  finding  compared  to baseline,  assessed  by [CONTACT_857782],  should  be recorded  as an AEs in the relevant  eCRF  form.  
 
9.1.13  Bacteriological  Testing  ‐ (Should  be  Taken  in Any  Case  of  Suspected  Infection  Before  
Starting  Antibiotic  Treatment)    
Bacteriological  tests  (from  the surgical  site drainage)  will be performed  in order  to assess  
infection  at the abdomen  surgical  target  incision  site. 
Bacteriological  tests  from  the wound  will be taken  if there  is a wound  discharge.  
The test kit will be forwarded  to ICON  Central  Laboratory  where  bacterial  growth,  
identification  and sensitivity  to Doxycycline  and other  common  practice  antibiotics,  will be 
assessed.  
Results  will be reported  back  to the referring  Investigator.      
 
22-2-2022Page 52 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195072]  experiences  Doxycycline  reactions  or other  allergies.  
Any abnormal  finding,  compared  to baseline,  should  be recorded  as an AE in the eCRF.  
9.1.15  Vital  Signs  
Systolic/diastolic  blood  pressure,  heart  rate,  & temperature  measurements  will be performed  
at each  visit after  [ADDRESS_1195073]  will be asked  for this information  at 
screening/admission.  
All measurements  and the time of measurements  will be recorded  in the eCRF. 
Any abnormal  finding  in the vital signs  measureme nts stated  above,  assessed  by [CONTACT_857783],  should  be recorded  as an AE in the eCRF.  
9.1.[ADDRESS_1195074] and present  illnesses  and 
surgeries  as well as medications  currently  being  taken  to treat  current  illnesses  will be 
recorded  by [CONTACT_149863].  
The medical  history  will include  alcohol  consumption,  tobacco  use, concurrent  diseases,  
detailed  allergy  status  (an allergy  questionnaire  will be completed)  and assessment  of possible  
infection.  Based  on the medical  history,  a Charlson  co‐morbidity  index  question naire  will be 
completed  for each  potential  subject.  
Subjects  with known  allergy  to Doxycycline  and/or  tetracycline  family  of drugs,  or to D‐PLEX’s  
excipi[INVESTIGATOR_857717].  
9.1.[ADDRESS_1195075]s  medical  
history.  
9.1.18  Assessment  of  Surgical  Site 
A blinded  Investigator/assessor  will inspect  the surgical  site and assess  the healing  of the 
surgical  wound.  Special  attention  should  be paid for signs  of infection.  The Investigator  should  
follow  the protocol  guidelines  for assessment  of SSI (see section  9.1.6  above).  
Surgical  site assessment  questionnaire,  that includes  potential  symptoms  of incision  infection      
 
22-2-2022Page 53 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
according  to CDC criteria  and ASEPSIS  scoring,  as well as modified  Vancouver  questionnaire1 
will be completed  by [CONTACT_857784].  
To help the independent  and blinded  adjudication  committee,  in cases  of a suspected  infected  
wound,  the assessor  is asked  to take a photographic  pi[INVESTIGATOR_857718],  using  
their  cellular  phone  per instructions  provided  as a separate  manual.  The photo(s)  should  
include  the incision  area with a sticker  of the subject  study  number  and date only and 
uploaded  to a save location  according  to the instructions  in the manual.   
Every  caution  is to be made  not to disclose  any of the subjects’  personal  data or features  such  
as tattoos.   
Every  effort  must  be made  to assess  the incisional  surgical  site at every  visit.  In case a subject  
is un‐ willing  or unable  to attend  a scheduled  visit,  a phone  conve rsation  should  be conducted  
with the subject,  his first degree  family  relative  or community  physician  and assessment  of the 
wound  per CDC should  be done.    
 
9.1.19  ASEPSIS:  (Additi onal  Treatment,  Serous  Discha rge,  Erythema,  Purulent  Exudate,  
Separation  of  Deep  Tissue,  Isolation  of  Bacteria,  Stay  Duration  as  Inpatient)  Scoring  
Method  
ASEPSIS  is an acronym  of wound  assessment  and treatment  parameters,  which  provides  
numerically  score  during  an inspection  of the surgical  site. The final score  is being  interpreted  
to severity  of wound  appearance  and the clinical  conseq uences  of the infection.  
Parameters  are: serous  exudate,  erythema,  purulent  exudate,  separation  of deep  tissue  and 
also antibiotic  therapy,  drainage  of pus under  local/  general  anaesthesia,  isolation  of 
pathogenic  bacteria  and stay as inpatient.  
 
 
9.1.20  Pharmacokinetics  
Doxycycline  pharmacokinetic  sampling  will be collected  in selected  sites from  all randomized  
subjects  in these  sites.  Abou t series  of   samples  per set will be analyzed  (sites  from  Czech  
Republic  will not participate  in the PK sub‐study).  About  series  will be analyzed  from  
subjects  receiving  2 vials,  about  series  will be analyzed  from  subjects  receiving  3 vials.    
Pharmacokinetic  samples  of  blood  will be collected  at each  PK time point,  prepared  and 
shipped  to the central  laboratory.  
 
 
 
1 Modified  Vancouver  questionnaires  will be completed  following  wound  closure      
 
22-2-2022Page 54 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
 Assign  (from  the eCRF)  a sequential  subject  number.  If a subject  is withdrawn  from  the 
study  or fails to undergo  the treatment  procedure,  the subject  number  cannot  be 
reassigned.  
 Record  demographics  (including  age, gender,  etc.) 
 Record  medical  history,  and complete  a Charlson  co‐morbidity  index.   
 Complete  allergy  questionnaire.  
 Record  concomitant  medication s. 
 Measure  height,  weight  and vital signs  (body  temperature,  heart  rate & blood  pressure).  
 Perform  physical  examination.  
 Hematology  and Chemistry  for Central  Laboratory  *. 
 Coagulation  and Urinalysis  in local  lab (tests  done  at the local  lab  performed  as a routine  
procedure  within  21 days prior  to surgery  and before  ICF signa ture  may be used  for 
eligibility  determination).  
 Pre‐application  Doxycycline  PK sampling  at selected  sites.  
 Pregnancy  test (if applicable)  ‐ local  serum  test or urine  dipstick  should  be performed  not 
more  than  1 day before  surgery.   
 Record  baseline  conditions  and planned  procedures  (any future  planned  elective  
procedure  should  be record ed so it will not be considered  an S/AE).  
 Eligibility  determination  according  to inclusion  and exclusion  criteria  
 *Pregnancy  test  should  be  performed  not  more  than  1 day  before  surgery.  
9.2.2 Visit  2: Surgery   Index  Procedure  (Day  0) 
Subjects  will be enrolled  into the study  and will be treated  with D‐PLEX  concomitantly  with 
SoC or SoC alone.  
The SoC for prophylactic  antibiotic  treatment,  used  in this study,  is based  on international  
guidelines3,19. It will be consistently  standardized  for all sites in the clinical  study  and is 
composed  of IV antibiotic  immediately  prior  to surgery,  with or without  mechanical  bowel  
preparation  in the preceding  several  days.  Each  site will use the same  pre‐defined  SoC for all 
its subjects  during  the study.  The IV antibiotic  treatment  will be composed  of the 1st or 2nd 
generation  of Cephalosporin  family  and Metronidazole  given  within  60 minutes before  surgery  
and should  be discontinued  maximum  24‐hour  post‐surgery.  In case of allergy  to the 
Cephalosporin/Penicillin  families  or Metronidazole,  other  IV antibiotic  may be used.  Pre‐
operation  prophylactic  oral antibiotic  is not allowed.   Mechanical  bowel  prepa ration  will be at 
the discretion  of the PI [INVESTIGATOR_857694]’s  SOP.  
      
 
22-2-2022Page 56 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
The following  will be performed  during  visit 2: 
 Confirmation  of eligibility  
 Randomization  via the eCRF  system  (For surgery  planned  for early  morning  time,  
randomization  via the eCRF  could  be done  a day in advance).  
 Vital signs  before  surgery  unless  taken  for screening  occurring  on the day of surgery.  
 Pre‐application  Doxycycline  PK sampling  (selected  sites,  if not done  during  screening)  
 Abdominal  Surgery  
 D‐PLEX  administration  (only  for subjects  randomized  to D‐PLEX  treatment  arm)  at the 
stage  of closure  of the abdominal  wall surgical  incision   
 Post‐application  Doxycycline  PK sampling  (at 2h & 6h)  selected  sites 
 AEs assessment  and recording  
 Concomitant  Medication  Review  
 
9.2.3 Visits  3  6: Follow ‐Up  Visits  (Days  1, 5 ,14  & [ADDRESS_1195076] ‐Surgery)  
Post‐operative  care will be performed  per SoC. Post‐operative  resumption  of activity  is at the 
discretion  of the Investigator  based  on the subject  medical  conditi on. 
The subsequent  follow ‐up visits  (visits  3‐5) will take place  at Day 1, Day [ADDRESS_1195077]‐
surgery.  These  visits  are usually  performed  after  this type of surgery.  
The additional  follow ‐up visit (visit  6) will take place  [ADDRESS_1195078]‐surgery  and is required  by 
[CONTACT_150407],  i.e., in addition  to the routine  visits  usually  performed  after  this kind of surgery.  
During  all the above ‐mentioned  visits,  the following  procedures  will be performed:  
 Vital signs  
 Assessment  of surgical  site, including  visual  examination:  
o Surgical  Site Assessment  questionnaires  (only  if wound  is not dressed).   
o Modified  Vancouver  questionnaires  will be completed  following  wound  closure  
from  day 14 onwards.  
 Hematology  and Chemistry  for Central  Laboratory  
 Post‐application  Doxycycline  PK sampling   selected  sites 
 AEs assessment  and recording  
 Concomitant  Medication  Review  
 Physical  examination  at visit 6 (Day 30) only  
 Urinalysis  will be performed  only at the discretion  of the Investigator.  
 Bacteriology  cultures  will be taken  if there  is wound  discharge.    
 
     
 
22-2-2022Page 57 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
9.2.4 Unscheduled  Visit(s)  
An unscheduled  visit may be performed  at any time  during  the study  at the subject’s  request  
or as deemed  necessary  by [CONTACT_149863].   
 The date and reason  for the unscheduled  visit will be recorded.   
 Assessment  of surgical  site,  
 Vital signs,   
 AEs  
 Concomitant  medications.   
 In addition,  any procedures  and evaluations  may be performed  as deemed  necessary  by 
[CONTACT_857785]’s  safety.  
This visit should  be recorded  in the eCRF,  including  all related  procedure.  
 
9.2.5 Visit  7 ‐ End  of  Study  ([ADDRESS_1195079] ‐Surgery)  
 Vital signs  
 Assessment  of surgical  site 
 Hematology  and Chemistry  for Central  Laboratory   
 Post‐application  Doxycycline  PK sampling   selected  sites 
 AEs assessment  and recording  
 Concomitant  Medication  Review  
 Physical  examination  
 Bacteriology  cultures  (if required)  
 
9.2.6 Study  Assessments  Summary  
Table  1 details  all planned  study  visits  and assessments.    
 
22-2-2022Page 58 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195080]  completed.  The end of the trial will be the 60‐days final follow ‐up visit 
for the last enrolled  subject.  
9.4 DISCONTINUATION/WITHDRAWAL  OF  PARTICIPANTS  & STOPPI[INVESTIGATOR_857693]  
Every  effort  will be made  to follow  all subjects  and collect  their  data until the end of the study.  
Subjects  participation  in a clinical  trial is voluntary,  and the subject  has the right  to withdraw  
consent  at any time without  penalty,  loss of benefit  or prejudice  to further  treatment.  
Although  a subject  is not obliged  to give his/her  reason(s)  for withdrawing  prematurely  
from  a trial,  the investigator  should  make  a reasonable  effort  to ascertain  the reason(s),  while  
fully respecting  the subject’s  rights.  
In the event  a subject  withdraws  consent,  every  effort  should  be made  to have  the subject  
return  for a final study  follow ‐up assessment  and the information  identified  for collection  at the 
60 days follow ‐up visit will be obtained  to the extent  possible.  Withdrawn  subjects  will not be 
replaced  (the justified  sample  size considers  an estimated  allowance  for attrition).  
The reason  for early  termination  should  be recorded  in the subjects  medical  records  and in the 
eCRF.   If more  than  one reason  is cited  for withdrawal,  study  personnel  should  identify  the 
most  significant  reason.    
The Investigator  may discontinue  a subject  from  participation  in the study  if the Investigator  
feels  that the subject  can no longer  fully comply  with the requirements  of the study  or if any of 
the study  procedures  are deemed  potentially  harmful  to the subject.  
The Sponsor  may suspend  or prematurely  terminate  this study  either  in an individual  
investigational  site, or the entire  study.  Reasons  for suspending  or early  terminating  the study  
by [CONTACT_857786],  documented  and reported  as applicable.  
EC/IRB  or regulatory  authority  may suspend  or prematurely  terminate  participation  in the study  
at the investigational  sites for which  they are responsible.  
If suspi[INVESTIGATOR_857719],  or when  so instructed  by 
[CONTACT_62814]/IRB  or regulatory  authorities,  the Sponsor  shall suspend  the clinical  trial while  the risk is 
assessed.  The Sponsor  shall terminate  the study  if an unacceptable  risk is confirmed.  
Data  that has already  been  collected  on withdrawn  subjects  will be retained  and used  for 
analysis,  but no new data will be collected  after  withdrawal.      
 
22-2-2022Page 60 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
10  NAME  & DESCRIPTION  OF  ALL  DRUGS  USED  IN  THE  TRIAL  
D‐PLEX  is the IP to be administered  in this study.  A comprehensive  description  is provided  below.  No 
additional  drugs  will be administered  as part of the requirements  of this clinical  study.  
10.1 STUDY  TREATMENT  D‐PLEX  
10.1.[ADDRESS_1195081]  Description  
D‐PLEX  is a new formulation  of extended  release  of Doxycycline.  The total  percentage  of 
Doxycycline  hyclate  in D‐PLEX  is    which  is equivalent  to  Doxycycline  free base.  
Doxycycline  is being  constantly  released  for approximately  4 weeks  following  
administration.  D‐PLEX  is biodegradable.  
D‐PLEX  is indicated  for prevention  of post abdominal  surgery  incisional  infection.  
This product  is a sterile  powder  and is intended  for a single  use. Each  10ml  vial contains  5g 
of D‐PLEX.  
10.1.[ADDRESS_1195082]  Composition  
D‐PLEX contains  the following  substances:  
Substance   Description  
Doxycycline  hyclate   Antibiotic  
 
Release  system  
 
 
10.1.[ADDRESS_1195083]  Handling  (storage  & preparation)  
D‐PLEX  is supplied  as sterile  powder  to be reconstituted  to paste  in the OR and is intended  for 
a single  administration.  
D‐PLEX  cannot  be injected!  
Each  10‐ml vial contains  5g of D‐PLEX.  
D‐PLEX  should  be stored  at 2‐8°C. 
The product  can be kept at room  temperature  for up to 12h until use (before  vial opening).  
Avoid  exposure  to extreme  heat.  
D‐PLEX  powder  will be hydrated  in a bowl,  using  standard  aseptic  techniques,  with sterile  
saline,  immediately  before  administration,  following  the instruction  described  here:  
     
 
22-2-2022Page 61 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
be  administered  should  be  poured  into  the  same  bowl.  
 
[IP_ADDRESS]  Product  Preparation  ‐ Step  2: 
To  be  conducted  by  a sterile  nurse  / surgeon : 
12. Slowly  hydrate  the D‐PLEX  powder  in the bowl  with the following  volume  of sterile  
saline:     
D‐PLEX  powder  from  2 vials  should  be hydrated  with 3.5ml  of sterile  saline.  
D‐PLEX  powder  from  3 vials  should  be hydrated  with 5ml of sterile  saline.  
13. Do not over hydrate.  
14. Mix the D‐PLEX  powder,  with sterile  saline  using  a sterile  spatula,  for approximately  
[ADDRESS_1195084]  it 
and return  to Step 1 for new preparation  of the D‐PLEX  paste.  
 
[IP_ADDRESS]  Product  Administration  ‐ Step  3:   
This  step  should  be  done  by  [CONTACT_857787] . 
 
16. The paste  is to be applied  by [CONTACT_857765],  after  wearing  a new set of sterile  gloves.  
17. Administer  the whole  quantity  of the D‐PLEX  reconstituted  paste  immediately  
after  hydration  and mixing.  The paste  should  be spread  on the entire  surface  of 
each  side of the abdominal  incisional  wall,  along  the whole  length  of the surgical  
wound  (including  muscle,  fat, and dermis).   
Do not apply  on top of the skin and above  the suture  line. 
18. In case application  was not done  immediately  and the paste  is over diluted,  
discard  the paste  and return  to Step 1 with new vial(s)  (package).    
19. Packages  (all 3 vials and box) should  be kept for inventory  documentation  
purposes  and returned  to the unblinded  study  coordinator  after  each  surgery.  
 
10.1.[ADDRESS_1195085]  to the SoC treatment.  The total  dose  
applied  at the surgical  site will be determined  based  on the surgical  incision  length.  A 
maximum  of three  vials (15g)  may be administered.  Therefore,  the total  amount  of 
Doxycycline  free base  for a single  surgical  procedure  with D‐PLEX  can reach  up to 163.8mg.      
 
22-2-2022Page 63 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195086])  in a single  application.  It is not expected  to occur  during  the study  as no 
more  than  maximum  of [ADDRESS_1195087].  
Overdose  of D‐PLEX  will be recognized  by [CONTACT_857788]  (OR) team.  
In case of an overdose  or adverse  drug  reaction,  treat  symptomatically  and institute  
supportive  measures.  Dialysis  does  not alter  serum  half‐life and thus would  not be of benefit  
in treating  cases  of overdose.  Per surgeon  decision,  the administered  D‐PLEX  can be removed  
by [INVESTIGATOR_1312]‐exploring  the surgical  incision  and washing  out the D‐PLEX.  
All overdoses  should  be recorded  and notified  to the Sponsor.   
If an SAE is associated  with the overdose,  the PI [INVESTIGATOR_857720].  
Information  on adverse  drug  reactions  of D‐PLEX  are provided  in the IB. 
10.1.9  Packaging  
D‐PLEX  is aseptically  packed  in sterile,  de‐pyrogenated  amber  (brown)  glass  vial and closed  
with a sterile  and de‐pyrogenated  rubber  stopper  and aluminium  flip‐off cap. 
Please  note  that the outer  surface  of the vial is not sterile.  Only  the vial content  is sterile.  
 
10.2 CONCOMITANT  MEDICATION  
10.2.1  Medication(s)/  Treatment(s)  Permitted  
Antibiotics  Treatment  per SoC allowed  in this Protocol:  
 Prophylactic  IV antibiotics  as per protocol.   
 Additional  antibiotics  (excluding  Doxycycline)  for  the  treatment  of medical  history  
condition  or AE. 
10.2.2  Medication(s)  Prohibited  During  the  Trial  
 Additional  prophylactic  antibiotics  (including  antimicrobial  sutures).   
 High steroids  dose  (more  than  80mg  per day).   
 Doxycycline  administration  during  the entire  trial period.  
 Any additional  investigational  drug  
 
10.3 PREPARATION  & LABELLING  OF  INVESTIGATIONAL  PRODUCT  (IP)  
The Investigational  Product  (IP) is manufactured  aseptically  at ,  at a 
Grade  A (ISO 5) clean  room.  The IP will be provided  to the investigational  site by    [INVESTIGATOR_67078] 
. upon  EC/IRB  approval  of the protocol  and the ICF, Investigator  Agreement  is 
signed,  and all key docu ments  required  by [CONTACT_857789]. 
D‐PLEX  is provided  as a sterile  and primarily  packaged  in a de‐pyrogenated  inert  glass  amber  vial     
 
22-2-2022Page 65 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
(10 ml), and each  product  vial contains  5g of D‐PLEX.   The sterile  vial is packaged  in a carton  box. 
Preparation  and labelling  of the IP will be completed  in accordance  with the relevant  GMP  
guidelines.  
Information  on the Product  Handling  (storage  & preparation)  can be found  in section  0 of this 
protocol.  
 
10.4 DRUG  ACCOUNTABILITY  
The Investigator  or designee  (i.e., SC, pharmacist)  is responsible  for ensuring  adequate  
accountability  of all used  and unused  study  drug.  This includes  acknowledgment  of receipt  of 
each  shipment  of study  product  (quantity  and condition)  and recoding  of subject  dispensing,  
returned  or destroyed  study  product.  Dispensing  records  will document  quantities  received  from  
the Sponsor  and quantities  dispensed  to subjects,  includi ng lot number,  date dispensed,  subject  
identifier  number,  and the name  [CONTACT_857821].  
All drug  supplies  and associated  documentation  will be periodically  reviewed  and verified  by [CONTACT_857790].  
Investigators  will be notified  in writing  of enrolment  completion.  All unused  D‐PLEX  vials must  be 
returned  to the Sponsor  when  enrolment  is complete  according  to Sponsors  instructions.  
10.5 RECORDING  & REPORTING  OF  ADVERSE  EVENTS  & REACTIONS  
The Investigator  or designated  site staff will be responsible  for detecting,  documenting  and 
reporting  events  that meet  the definition  of an AE or SAE. 
10.6 DEFINITIONS  
10.6.1  Adverse  Event  (AE)  
Any untoward  medical  occurrence  in a patient  or clinical  investigation  subject  administered  a 
pharmaceutical  product  and which  does  not necessarily  have  a causal  relationship  with this 
treatment.   
NOTE:  An AE can therefore  be any unfavourable  and unintended  sign (including  an abnormal  
clinically  significant  laboratory  finding),  symptom,  or disease  (new  or exacerbated)  temporally  
associated  with the use of a medicinal  product.  
 
Examples  of events  meeting  the definition  of an AE include:  
● Exacerbation  of a chronic  or intermittent  pre‐existing  condition  including  either  
an increase  in frequency  and/or  grade  of the condition.  
● New conditions  detected  or diagnosed  after  study  treatment  administration  even  
though  it may have  been  present  prior  to the start  of the study.  
● Signs,  symptoms,  or the clinical  sequelae  of a suspected  interaction  of study  
medication  with any other  treatment  provided  to the subject.      
 
22-2-2022Page 66 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
● Signs,  symptoms,  or the clinical  sequela  of suspected  overdose  of either  study  
treatment  or a concomitant  medication  (overdose  per se will not be reported  as 
an AE). 
Lack  of efficacy  or failure  of expected  pharmacology  action  per se will not be reported  as 
an AE or SAE. However,  the signs  and symptoms  and/or  clinical  sequelae  resulting  from  lack of 
efficacy  will be reported  if they fulfil the definition  of an AE or SAE. 
Events  that do  not meet  the definition  of an AE include:  
● Medical  or surgery  procedure  (e.g. endoscopy,  appendectomy);  the condition  
that leads  to the procedure  should  be recorded  as an AE. 
● Situations  where  an untoward  medical  occurrence  did not occur  (social  and/or  
convenience  admission  to a hospi[INVESTIGATOR_307]).  
● Anticipated  day‐to‐day fluctuations  of pre‐existing  disease(s)  or condition(s)  
present  or detected  at the start  of the study  that do not worsen.  
● The disease/  disorder  being  studied,  or expected  progression,  signs,  or symptoms  
of the disease/  disorder  being  studied,  unless  more  severe  than  expected  for the 
subjects  condition.  
10.6.2  Adverse  Drug  Reaction  (ADR)  
Any untoward  and unintended  response  in a subject  to an investigational  medicinal  product  
which  is related  to any dose  administered  to that subject.  The definition  implies  a reasonable  
possibility  of a causal  relationship  between  the event  and the IP. 
This includes  medication  errors,  uses outside  of protocol  (including  misuse  and abuse  of  
product).   
10.6.3  Serious  Adverse  Event  (SAE)  
SAE is any untoward  medical  occurrence  that,  at any dose:  
● Death  or Results  in death  
● Is life‐threatening  
NOTE:  The term  life‐threatening  in the definition  of serious  refers  to an event  in 
which  the subject  was at risk of death  at the time of the event.  It does  not refer  to 
an event,  which  hypothetically  might  have  caused  death,  if it was more  severe.  
● Requires  hospi[INVESTIGATOR_857721].  
NOTE:  In general,  hospi[INVESTIGATOR_857722]  
(usually  involving  at least  an overnight  stay)  at the hospi[INVESTIGATOR_857723]/or  treatment  that would  not have  been  appropriate  in the 
physicians  office  or outpatient  setting.  Complications  that occur  during  
hospi[INVESTIGATOR_857724]. If a complication  prolongs  hosp italization  or fulfils  any 
other  serious  criteria,  the event  is serious.  When  in doubt  as whether  
hospi[INVESTIGATOR_059]  occurred  or was necessary,  the AE should  be considered  serious.  
Hospi[INVESTIGATOR_857725] a pre‐existing  condition  that did not 
worsen  from  baseline  is not considered  an SAE.     
 
22-2-2022Page 67 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
10.7.5  Seriousness  
Seriousness  as defined  for an SAE in section  10.6.3.  
 
10.8 DOCUMENTATION  AND  REPORTING  OF  SAE  AND  SSI  
All SAEs  and SSIs should  be reported  to the Sponsor  within  24 hours  of knowledge  by a blinded  
investigator.  
SAEs  will be reported  through  the study  eCRF.  In case the eCRF  is not available,  the  blinded  
investigator  will complete  the Sponsors  SAE form  and the form  will be emailed  to the Sponsor  
to the following  email:     within  24 hours  of knowledge.  
It is the PIs responsibility  to ensure  SAE queries  raised  by [CONTACT_857791].  
The information  should  be completed  as fully as possible  and contain:  
1. SAE Term   if diagnosis  was provided,  the SAE term  should  be the diagnosis,  
otherwise,  symptoms  should  be reported  as separated  AE/SAEs.   
2. SAE onset  date ‐ report  the start  date the event  became  SAE.  
3. SAE end date ‐ Report  the date the subjects  medical  condition  resolved  or 
stabilised,  or the date of discharge  from  hospi[INVESTIGATOR_307].   
Should  signs  and symptoms  continued  following  discharge,  report  them  as an AE  
4. Seriousness  criteria  
5. Severity  (mild,  moderate,  severe)  
6. Relatedness  to the surgical  procedure  
7. Relatedness  to the IP (Related/Not  Related)  
8. Action  taken  to resolve  the SAE (e.g. Treatment,  Other  Action)  
9. Outcome  (Ongoing,  Resolved  with Sequelae,  Resolved,  Death)  
10. SAE Narrative  ‐ brief  and comprehensive,  including  clinical  symptoms  and 
accompanied  with a simple,  brief  description  of the event,  Lab data results,  
timelines  and other  important  information.   
10.9 TIME  PERIOD  AND  FREQUENCY  FOR  REPORTING  AES  
The Investigator  and site staff are responsible  for detecting,  documenting,  and reporting  events  
that meet  the definition  of an S/AE.  or  
AEs will be collected  from  the time  of randomization  throughout  the study,  and until study  
termination  at visit 7 (60 days after  surgery).  
In addition,  any SAE assessed  as related  to study  participation  (e.g.,  protocol ‐mandated  
procedures,  invasive  tests  etc.),  will be recorded  from  the time subject  consents  to participate  in 
the study.  
After  the termination  of the clinical  trial,  newly  reported  SAEs  which  are suspected  to be related  
to the IP by [CONTACT_857792], and therefore  reported  to the Sponsor  will be collected,  documented,  
and reported  as required  by [CONTACT_857793].      
 
22-2-2022Page 70 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
10.11  DEVELOPMENT  OF  SAFETY  UPDATE  REPORTS  
The Sponsor  will prepare  a Development  Safety  Update  Report  (DSUR)  on an annual  basis  and 
submit  it to ECs/IRBs  and the Ministry  of Health/Regulatory  Authority  per local  and global  
regulations.  The DSUR  will contain  an annual  review  and evaluation  of pertinent  safety  
information  collected  during  the reporting  period  related  to the IP. 
10.12  THE  TYPE  & DURATION  OF  THE  FOLLOW ‐UP  OF  SUBJECTS  AFTER  AES  
AEs not related  to the study  product  should  be followed  up until resolution,  permanent  outcome  
or subjects  study  termination,  whichever  is earliest.  
AEs suspected  to be related  to the IP should  be followed  up until resolution  or permanent  
outcome.  
For SAE ‐ in case relevant  information  is not available  at the time when  the first report  becomes  
available,  the Investigator  should  report  the known  information  within  [ADDRESS_1195088] 
awareness.  Once  additional  information  is received,  the Investigator  should  fill in the missing  
follow ‐up information  in the eCRF  within  24 hour  of the awareness  of the new available  
information.  
It is the responsibility  of Investigators  to inform  the local  Ethics Committee  of SAEs  (whether  IP 
related  or not) as required  by [CONTACT_857794].  
11  NOTIFICATION  OF  PROTOCOL  DEVIATION  
The Investigator  is responsible  for ensuring  the study  is conducted  in accordance  with the 
procedures  and evaluations  described  in this protocol.  
It is within  the site’s  Sponsor  to notify  the regulatory  authority  in writing  of any serious  breach  
of (i) The conditions  and principles  of GCP in connection  with that trial;  or (ii) The protocol  
relating  to that trial,  as amended  from  time to time,  within  7 days of becoming  aware  of that 
breach.  
The Sponsor  will be notified  immediately  of any case where  the above  definition  applies  during  
the trial.    
12 DATA  MANAGEMENT  & QUALITY  ASSURANCE  
12.[ADDRESS_1195089]s  name  [CONTACT_857822].  The subjects  date 
of birth  and trial unique  identification  number  will be used  for identification.  
12.2 DATA  COLLECTION  TOOLS  & SOURCE  DOCUMENT  IDENTIFICATION  
Primary  data collection  based  on source ‐documented  hospi[INVESTIGATOR_857726]/or  clinic  chart  reviews  will be 
performed  clearly  and accurately  by [CONTACT_857795].  The Sponsor  or designee  will perform  clinical  monitoring  throughout  the study.  
It is the responsibility  of the Investigator  to ensure  the accuracy,  completeness,  legibility,  and 
timeliness  of all data reported  to the Sponsor  in the eCRFs  and in all required  reports.      
 
22-2-2022Page 72 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
12.3 DATA  HANDLING  & ANALYSIS  
The procedures  for data review  and query  management  are described  in the Data  Management  
Plan and the Edit Checks  Specification  Table.  Data  will be reviewed  throughout  the study,  in a 
blinded  manner,  according  to these  documents.  
Data  will be collected  using  eCRFs  that are specifically  designed  for this study.  The data colle cted 
on the eCRFs  will be captured  in a clinical data management  system  (CDMS)  that meets  the 
technical  requirements  described  in 21 CFR Part 11 and EU regulations.  The CDMS  will be fully 
validated  to ensure  that it meets  the scientific,  regulatory,  and logistical  requirements  of the 
study  before  it is used to capture  data from  this study.  Before  using  the CDMS,  all users  will 
receive  training  on the system  and study ‐specific  training.  After  they are trained,  users  will be 
provided  with individual  system  access  rights.  
Data  will be collected  at the investigational  center  by [CONTACT_857796],  and eCRFs  must  be completed  for each  screened  subject  according  to their  source  
documents.   
Subject  identity  should  not be discernible  from  the data provided  on the eCRF.  
A comprehensive  validation  check  program  will verify  the data and automatically  generate  
discrepancies  for resolution  by [CONTACT_149863].  
Data  will be verified  using  the source  data by [CONTACT_857797].    
All data collected  will be approved  by [CONTACT_857798].  This approval  
acknowledges  the Investigators  review  and acceptance  of the data as being  complete  and 
accurate.  
[ADDRESS_1195090]  KEEPI[INVESTIGATOR_1645]  & ARCHIVING  
The investigator  shall arrange  for the retention  of all study  records  for at least  15 years  after  
completion  of the study.  
The Investigator  should  ensure  that the following  records  are maintained:  
1. Subject  files containing  copi[INVESTIGATOR_857727]. 
2. Investigator  files containing  copi[INVESTIGATOR_857728]  
(e.g. signed  Investigators  Agreement,  Curricula  Vitae  for the principal  and all sub‐
Investigators,  copy  of the EC/IRB  approval  of the protocol  and Informed  Consent  Form,  
copi[INVESTIGATOR_857729]/Sponsor  etc.).  In addition  to these  records required  
by [CONTACT_19124],  the Sponsor  requests  that the Investigator  keep  a copy  of the Financial  
Agreement  between  CRO/Sponsor  and the Investigator.  
3. Files containing  copi[INVESTIGATOR_857730] (IPAL)  or 
an equivalent  form  approved  by [INVESTIGATOR_30909]/Sponsor,  and the Investigators  Brochure.  
No records  will be destroyed  without  the written  consent  of the Sponsor.  It is the responsibility  
of the Spons or to inform  the Investigator  when  these  documents  no longer  need  to be retained.      
 
22-2-2022Page 73 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
14 STATISTICAL  ANALYSIS  CONSIDERATIONS   
This protocol  describes  the statistical  analysis  as it is foreseen  at the time of planning  the study.  A 
fully detailed  Statistical  Analysis  Plan (SAP)  will be produced  and finalized  after  finalizing  the protocol  
and before  breaking  the blind  of the study.  The SAP serves  as a compliment  to the protocol  and 
supersedes  it in case of differences.  In case of major  differences  between  the protocol  and SAP, a 
protocol  amendment  will be considered.  Any deviations  from  the statistical  analyses  planned  in the 
protocol  will be documented  in the SAP and any deviations  from  the statistical  analyses  planned  in 
the SAP will be docu mented  in the final clinical  study  report.  
 
14.[ADDRESS_1195091]  to the primary  
efficacy  endpoint.  It was assumed  that the SSI rate in the SOC arm would  be 16% and that D‐
PLEX  +SOC  will have  effect  of 50% on this rate (halving  infection  rate)  relative  to SOC alone,  thus 
8% infection  rate in D‐PLEX+SOC  arm.  Assuming  rate equal  to   for both  arms  with regard  30‐
day treatment  failure  due to all‐cause  mortality  or re‐intervention  in the target  incision,  due to 
suspected  SSI or due to poor  wound  healing,  includi ng wound  dehiscence,  the assumed  
treatment  failure  rates  were     and  , for SOC and DPLEX+SOC,  respectively.  A sample  of 
882 total  subjects  provides  90% power  to detect  the assumed  difference  in treatment  failure  
rate using  chi square  test, and to account  for the planned  interim  analysis  for efficacy  (to be 
performed  with a two‐sided  α=0.01),  a conservative  two‐sided  α=0.04  level  of significance  was 
employed.  In order  to account  for an anticipated  about  5% lost‐to‐follow ‐up rate,  a minimum  of 
950 subjects  (475/treatment  arm)  will be enrolled.    
 
14.1.1  Interim  analysis  for  stoppi[INVESTIGATOR_857731],  or  un ‐blinded  sample  size  re ‐
estimation ‐ 
One comparative  interim  analysis  for an early  efficacy  or futility  stop,  or sample  size re‐
estimation  will be conducted  when  about  750 subjects  will complete  1‐month  Follow ‐up and 
evaluated  for the primary  endpoint.   The interim  analysis  will include  a group ‐sequen tial 
design  stoppi[INVESTIGATOR_857699],  combined  with unblinded  sample  size re‐
assessment  based  on the Promising  Zone  approach.  The outcome  of this interim  analysis  will 
be either  early  stoppi[INVESTIGATOR_857732] (950 subjects)  or continue  
with sample  size increased  up to a total  of 1400  subjects,  only if the comparative  result  falls in 
a predefined  Promising  Zone.  The interim  decision  will be made  by [CONTACT_857799] a pre‐planned  interim  analysis  plan,  and comparative  information  will be 
maintained  confidential  within  the independent  statistician  until the study  finally  unblinded.   
The pre‐defined  stoppi[INVESTIGATOR_857733]‐calculation  will be detailed  in an Interim  
analysis  Plan to be finalized  before  the unblinding  takes  place.      
 
22-2-2022Page 74 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
 
 
14.2 ANALYSIS  POPULATIONS  
The following  analysis  populations  will be defined  for the study:  
 
14.2.1  Intention  to  Treat  (ITT)  Set  
 The ITT analysis  set will consist  of all subjects  who have  been  randomized  to receive  either  D‐
PLEX  plus SoC or SoC alone.  In this analysis  set, treatment  will be assigned  based  on the 
treatment  to which  subjects  were  randomized,  regardless  of which  treatment  they actually  
received.  
 
14.2.[ADDRESS_1195092]  been  randomized  and treated  with 
D‐PLEX+SoC  or SoC alone.  In this population,  treatment  will be assigned  based  upon  the 
treatment  the subjects  actually  received,  regardless  of the treatment  to which  they were  
randomized.  
14.2.3  Modified  Intention  to  Treat  (mITT)  Set   
The mITT  analysis  set is a subset  of the ITT set and will consist  of all subjects  randomized  and 
treated  with D‐PLEX+SoC  or SoC alone  who underwent  the index  surgery,  and have  no 
eligibility  criteria  deviation.  In this population,  treatment  will be assigned  based  upon  the 
treatment  to which  subjects  were  randomized,  regar dless  of the treatment  they actually  
received.  Exclusion  from  the mITT  population  will be determined  in a blinded  manner  prior  to 
database  lock.  Subjects  who will die during  the study  will not be excluded  from  the mITT  
population.  
14.2.4  Per  Protocol  (PP)  Set   
The PP analysis  set is a subset  of the mITT  set and will consist  of all subjects  in the mITT  who 
have  no major  protocol  deviations  and were  assessed  for the primary  endpoint  (i.e. completed  
the Day [ADDRESS_1195093]‐surgical  SSI or death  or 
re‐intervention  in the index  surgery,  due to suspected  SSI or due to poor  wound  healing,  
including  wound  dehiscence).  
The analysis  of the primary  and key secondary  efficacy  endpoints  will be performed  on the ITT, 
mITT  and PP populations,  with the ITT population  serving  as the primary  analysis  set. Analyses  
of additional  secondary  efficacy  endpoints  will be performed  on the population s as described  
in the Statistical  Analysis  Plan (SAP)  for the study.  Analyses  of safety  will be performed  on the 
safety  analysis  set. Baseline  subject  characteristics  and demographics  will be summarized  for 
the ITT population.  
     
 
22-2-2022Page 75 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195094]  Characteristics  
Baseline  and demographic  characteristics  will be summarized  for all subjects  in the ITT 
population  by [CONTACT_857800].  Continuous  variables  will be displayed  via 
summary  statistics  (number  of non‐missing  observations,  mean,  median,  standard  deviation,  
minimum,  and maximum).  Categorical  variables  will be summarized  via counts  and 
percentages.  
 
14.3.2  Primary  Endpoint  Analysis  
The primary  objective  of the study  is to assess  the anti‐infective  efficacy  of DPLEX+SOC  over a 
period  of [ADDRESS_1195095] operation,  by [CONTACT_857746]  (SSI),  defined  as 
superficial  and/or  deep  infection,  in the index  (target)  incision,  compared  to the SoC alone  
control  arm.  
The primary  analysis  will be based  on a composite  treatment ‐failure  (Yes/No)  variable,  
indicating  if a subject  had at least  one treatment ‐failure  event,  defined  as follows:  SSI event,  
occurring  within  [ADDRESS_1195096] abdominal  surgery  (up to and including  the 30‐days follow ‐up 
visit)  and determined  by a blinded  and independe nt adjudication  committee;  or death  (from  
any reason)  within  30‐days from  surgery.  In addition,  re‐intervention  at the target  incision  site 
within  30 days of the index  operation  (due to suspected  SSI or due to poor  wound  healing,  
including  wound  dehiscence,  as determined  by [CONTACT_857801])  will be 
considered  a treatmen t failure  for the primary  ITT analysis.  To note,  re‐intervention  at a 
different  access  point  than  the index  wound  outcome  or re‐intervention  due to any other  
reason  than suspected  SSI or due to poor  wound  healing,  including  wound  dehiscence,  will not 
be considered  as a treatment  failure  in the primary  analysis..  In the rare case of indeterminate  
SSI outcome  (i.e. missing  outcome  due to other  reasons  than  death),  it will also be counted  as 
treatment  failures  for the primary  analysis.  
The number  and proportion  of subjects  with treatment ‐failure  as defined  above  will be 
tabulated  per treatment  group. A 95% confidence  interval  will be constructed  for each  
proportion.  A Cochran  Mantel ‐Haenszel  (CMH)  test will compare  the proportion  of treatment ‐
failure  between  the two groups,  using  the study  stratification  factors  used  for randomization,  
and corresponding  risk difference  estimate  will be presented  with 95% confide nce interval  
(using  the method  of MantelHaenszel  stratum  weights,  as applied  in the COMMONRISKDIFF  
option  in the SAS FREQ  procedure).  The following  hypotheses  will be tested  for a significant  
difference  in the composite  treatment ‐failure  proportions  between  D‐PLEX+SoC  (PDPLEX) and 
SoC (PSoC) treatment:      
 
22-2-2022Page 76 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
H0: PDPLEX = PSoC 
vs. 
H1: PDPLEX ≠ PSoC 
The interim  analysis  adjusted  significance  level  will be used  for this test, refer  to 14.3.4  for 
details.  In the case of small  number  of events  (less than  5 events  in any study  arm),  the Fisher  
exact  test will be used.  
The number  and percent  of each  of the failure  types  comprising  the primary  endpoint  will be 
described  by [CONTACT_19313].  
Sensitivity  and supportive  analyses  for the primary  endpoint  analysis  will be defined  and 
detailed  in the statistical  analysis  plan.  These  will address  the following  aspects:   
 Using  the mITT  and PP populations  
 To account  for the possibility  of errors  in values  of stratification  factors  used  for randomi ‐
zation,  the primary  analysis  will supportively  be repeated  using  the correct  values.  
 Difference  between  the treatment  and control  groups  when  controlling  for possible  
imbalance  in important  baseline  factors  will be analysed  by [CONTACT_857802]  a multiple  logistic  regression  model.  The list of baseline  
variables  will be finalized  in the SAP. 
 Sensitivity  analysis  for the imputation  of missing  data due to other  reason  than death  
(please  refer  to Section  14.3.7).  
 Descriptive  statistics  of the incidence  of re‐interventions  at the target  incision  site due to 
other  reasons  than suspected  SSI or due to poor  wound  healing,  including  wound  
dehiscence  within  30 days of the index  operation.  Analysis  where  these  events  will also 
be considered  as treatment  failure  (in addition  to the primary  endpoint  defined  above)  
will also be performed.  
 
14.3.3  Secondary  Efficacy  Endpoint  Analysis  
[IP_ADDRESS]  Key  secondary  efficacy  endpoint  
The key secondary  endpoints  defined  for the study are: 
● Infection  rate as measured  by [CONTACT_857803],  occurring  within  [ADDRESS_1195097] abdominal  surgery  and determined  by a 
blinded  and independent  adjudication  committee.  
● Number  (percent)  of subjects  with at least  1 score  of ASEPSIS  > [ADDRESS_1195098] key secondary  
endpoint  above,  will be tabulated  per treatment  group.  A 95% confidence  interval  will be     
 
22-2-2022Page 77 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
constructed  for each  proportion.  A Cochran  Mantel ‐Haenszel  (CMH)  test will compare  the 
proportion  of SSI between  the two groups,  using  the study  stratification  factors  used  for 
randomization,  and corresponding  risk difference  estimate  will be presented  with 95% 
confidence  interval  (using  the method  of MantelHaenszel  stratum  weights,  as applied  in 
the COMMONRISKDIFF  option  in the SAS FREQ  procedure).  In the case of small  numb er of 
events  (less than  5 events  in any study  arm),  the Fisher  exact  test will be used.  This 
endpoint  will be formally  tested  only if the primary  endpoint  is significant,  using  two‐
sided  5% significance  level.   
The number  and proportion  of subjects  who reached  a score  of ASEPSIS>[ADDRESS_1195099] key secondary  endpoint  is significant,  using  two‐
sided  5% significance  level.  
Missing  data strategy  for these  endpoints  is described  in section  14.3.7.  The primary  
analysis  for these  endpoints  will be ITT and sensitivity  analyses  will be defined  and 
detailed  in the SAP. 
 
[IP_ADDRESS]  Additional  secondary  efficacy  endpoint  
Details  regarding  the analyses  of the additional  efficacy  endpoints  are described  in the 
SAP for the study.  
 
14.3.4  Type  1 error  control  
The overall  study ‐wise type I error  will be 5%.  
To protect  the study  from  type I error  inflation,  the key secondary  endpoints  will be 
interpreted  inferentially  only if a statistically  significant  treatment  effect  (p‐value  f0.05)  is 
detected  in the primary  endpoint.  Type  I error  will be further  controlled  for the key 
secondary  endpoints  by [CONTACT_857804],  i.e., the 2nd key secondary  
endpoint  will be formally  analysed  only in case the 1st key endpoint  will be statistically  
significant  (p‐value  f0.05).  
The additional  secondary  endpoints  will be used  to enhance  understanding  the beneficial  
effect  of D‐PLEX  and there  is no plan for formal  inference  for these.  Thus,  no multiplicity  
control  is further  planned  beyond  the key secondary  endpoints.  
To account  for the option  of early  stoppi[INVESTIGATOR_857734],  the type‐1 error  spending  approach  
will be utilized.  The interim  analysis  is planned  when  about  750 subjects  in total  will be en‐
rolled  and have  the chance  to complete  1‐month  visit,  and an alpha  level  of 1% regardless  of 
the exact  number  of subjects  included  in the analysis  will be used.  For strict  control  of the 
overall  type‐1 error,  the alpha  for the final analysis  (in case the study  does  not stop at interim)  
will be calculated  based  on the actual  information  time  of the interim  analysis.        
 
22-2-2022Page 78 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
The Promising  Zone  approach  (Mehta  and Pocock  2011 ) was chosen  to rigidly  control  
study  overall  type‐1 error  due to the unblinded  comparative  size re‐estimation  at the time  
of interim  analysis,  and its planned  implementation  strictly  follows  the rules  that increase  
sample  size only if comparative  results  fall in a pre‐defin ed Promising  Zone,  thus allowing  
final analysis  to be preserved  without  further  need  for statistical  adjustment  (beyond  
adjustment  due to the interim  efficacy  analysis  as described  above).  
14.3.5  Subgroup  analysis   
The primary  and key secondary  endpoints  will be analysed  by [CONTACT_857805]:  f20 cm, >[ADDRESS_1195100]  one treatment ‐emergent  adverse  
event  (TEAE)  and the number  and proportion  of subjects  reporting  at least  one TEAE  by 
[CONTACT_857806]  (SoC)  and preferred  term will be reported.  This analysis  will be 
repeated  for serious  AEs (SAEs)  and for treatment ‐related  AEs. Additional  summaries  of TEAEs  
will be performed  by [CONTACT_857807].     
Vital sign measurements  and clinical  laboratory  parameters  will be summarized  via descriptive  
statistics  (mean,  standard  deviation,  median,  minimum,  maximum,  and number of non‐
missing  observations)  for each  post‐treatment  time point.  Shift tables  will be constructed  for 
physical  exams  to display  any changes  in body  system  findings  over time.  Responses  to the 
Modified  Vancouver  Scar Scale  will be summarized  with counts  and proportions  by [CONTACT_857758].  
Additional  analyses  of safety  will be described  in the SAP for the study.  
 
14.3.7  Handling  of  Missing  Data  
To be recalled,  in the calculation  of the primary  endpoint  (section  14.3.2),  deaths  occurring  
within  the first [ADDRESS_1195101] abdominal  index  surgery  are addressed  as treatment  failure  
events  and thus are not considered  missing  data problem,  in either  of the primary  or 
sensitivity  and supportive  primary  endpoint  analysis.  
To note,  re‐intervention  in the target  incision  occurring  within  the first [ADDRESS_1195102]  missing  primary  efficacy  endpoint  data due to other  reasons  
than death  (i.e. missing  Day 30 SSI assessment  (regardless  of reason)  or performed  out of pre‐
specified  visit window)  and have  not already  been  identified  as treatment  failures  due to 
having  experienced  any adjudicated  SSI event  or re‐intervention  in the target  incision,  due to 
suspected  SSI or due to poor  wound  healing,  including  wound  dehiscence,  will be imputed  as 
treatment  failure.      
 
22-2-2022Page 79 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
 
For the purpose  of the sensitivity  analyses  to the primary  efficacy  endpoint  analysis,  missing  
data (arising  from  other  reasons  than death)  will be imputed  as follows:  
When  using  ITT population:  
1.Using  Multiple  Imputation  (MI) technique  
2.Imputing  as not treatment  failure  
When  using  mITT  and PP populations:  no imputation  will be performed  (i.e., a compl ete case 
analysis  will be used).  
Time  to adjudicated  SSI during  [ADDRESS_1195103] index  surgery  endpoint  will handle  the missing  
values  as censored.  
There  will be no imputation  of missing  data for all other  study  endpoints  (i.e., a complete  case 
analysis  will be used),  unless  otherwise  noted  for a specific  analys is. 
Full details  on sensitivity  analyses  for handling  missing  data for the primary  endpoints  and for 
the key secondary  endpoints  will be provided  in the SAP. 
 
14.3.8  Interim  Analyses  
One formal  analysis  to stop the study  early  for efficacy  or safety  is planned  for this study.  The 
interim  analysis  will include  a group ‐sequential  design  stoppi[INVESTIGATOR_857735],  
combined  with comparative  sample  size re‐estimation  (please  refer  to section  14.1.1).   
 
14.4 NAME  [CONTACT_857823]   
14.4.1  DATA  MONITORING  COMMITTE  (DMC)  
An independent  of the Sponsor/Investigator  involved  in the study  DMC  will be utilized  in this 
study  to ensure  external  objective  medical  and/or  statistical  review  of safety  issues  in order  to 
protect  the ethical  and safety  interests  of subjects  and to maintain  the scientific  validity  of the 
study.   
In order  to maintain  blinding  in communication  with the DMC,  an Independe nt Biostatistician  
separate  from  the study  team  will be appointed  to provide  required  information  to the DMC.  
Blinded  tables  and listings  will contain  pooled  blinded  data and will be distributed  to PolyPid  
personnel  by [CONTACT_857808].  Unblinded  tables  and listings  will contain  unblinded  
data and will be distributed  only to DMC  voting  members  directly  by [CONTACT_857808]  
(at the beginning  of such  e‐mails,  the unblinded  statistician  will detail  who are the unblinded  
team  mem bers specifically  for each  case and with whom  information  can be forwarded  to or 
discussed  with).  
Data  management  and clean ‐up will be done  on blinded  data sets.  
The schedule  of any planned  interim  analysis  and the analysis  plan for DMC  review  is 
describe d in the charter.      
 
22-2-2022Page 80 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195104]  to the interim  analysis,  the interim  decision  will be made  by [CONTACT_857809] a pre‐planned  interim  analysis  plan,  and comparative  information  will be 
maintained  confidential  within  the independent  statistician  until the study  finally  unblinded.  
 
14.4.2  ENDPOINTS  ADJUDICATION  COMMITTEE  (EPAC)  
An independent  of the Sponsor/Investigator  involved  in the study  and blinded  to treatment  
arm Endpoint  Adjudication  Committee  will be established.   
This committee  is an independent  clinical  events  classification  committee,  composed  of a 
minimum  of 3 experts  in the fields  of surgeries  and infectious  disease,  who will remain  blinded  
to the treatment  assignments.  
All information  collected  regarding  efficacy  (abdominal  wall infection)  will be reviewed  by [CONTACT_941] 
Endpoint  Adjudication  Committee.  In addition,  the committee  will review  all death  cases  to 
verify  if they may be related  to abdominal  wall infection,  IP or other  cause.  It is within  their  
scope  to make  an independent  decision  whether  a subject  has met the primary  endpoint  or to 
assess,  in case of a death,  for its relationship  to infection  or to the study  drug.  
Vote  followed  by [CONTACT_857810]  2 out of 3. 
Committees  adjudication  blinded  review  will be forwarded  to the Sponsor.   
In case of dispute  between  Investigator  assessment  of infection  and the committees  
assessment,  Endpoint  Adjudication  Committees  assessment  on primary  endpoint  evaluation  
will overrule  the Investigator  assessment.   
[ADDRESS_1195105],  
hospi[INVESTIGATOR_857736]. 
The Investigator  will permit  trial‐related  monitoring,  audits,  EC/IRB  review,  and regulatory  
inspection(s),  providing  direct  access  to source  data/documents.  Trial participants  are informed  of 
this during  the informed  consent  discussion.   Participants  will consent  to provide  access  to their  
medical  notes.  
16 ETHICS  & REGULATORY  REQUIREMENTS  
The protocol,  ICF and Authorization  for the Use and Disclosure  of Health  Information  or country  
specific  confidentiality  requirements  must  be reviewed  and approved  by [CONTACT_857811]/IRB  and 
the Sponsor  before  subject  enrolment.  Changes  to the protocol  must  be approved  in writing  by [CONTACT_857812]/IRB  (as applicable)  before  the change  is implem ented.  
Prior  to subject  enrolment,  a signed  copy  of the EC/IRB  approval  letter  addressed  to the Investigator  
must  be submitted  to the Sponsor,  certifying  study  approval.   Investigators  are responsible  for 
submitting  and obtaining  initial  approval  and continuing  approval  from  the EC/IRB  and forwarding  
copi[INVESTIGATOR_857737].  The original  letters  are to be kept in the inves tigational  
centers’  Regulatory  Binder  designated  for this study.    
The Investigator  will notify  the Sponsor  immediately  of withdrawal  of EC/IRB  approval.        
 
22-2-2022Page 81 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
17 QUALITY  CONTROL  (STUDY  MONITORING)  
In accordance  with applicable  regulations,  GCP,  and Sponsors  procedures,  the site will be contact[CONTACT_857813],  study  requirements,  and 
their  responsibilities  to comply  with regulatory,  ethical,  and Sponsors  requirements.   When  
reviewing  data collection  procedures,  the discussion  will include  identification,  agreement  and 
documentation  of data items for which  the CRF will serve  as the source  document.  
The Investigator  and the head  of the medical  institution  (where  applicable)  agree  to allow  the 
monitor  direct  access  to all relevant  documents  and to allocate  their  time and the time of their  staff 
to monitor  to discuss  findings  and any issues.  
Monitoring  visits  will be conducted  in a manner  to ensure  that the: 
● Data  are authentic,  accurate,  and complete.  
● Safety  and rights  of subjects  are being  protected.  
● Study  is conducted  in accordance  with the currently  approved  protocol  and any other  study  
agreements,  ICH GCP,  and all applicable  regulatory  requirements.  
A trial specific  monitoring  plan will be established  for the study.  The trial will be monitored  according  
to the agreed  plan.  
18 QUALITY  ASSURANCE  (QA)  
To ensure  compliance  with GCP and all applicable  regulatory  requirements,  Sponsor  may conduct  a 
QA assessment  and/or  audit  of the site. Regulatory  authorities  may conduct  a regulatory  inspection  
at any time during  or after  completion  of the study.  
The Investigator  (and institution)  agree  to grant  the advisor(s),  auditor(s)  and inspector(s)  direct  
access  to all relevant  documents  and to allocate  their  time and the time of their  staff to discuss  the 
conduct  of the study,  any findings/relevant  issues  and to implement  any corrective  and/or  
preventive  actions  to address  any findings/issues  identified.  
19 INSURANCE  
The Sponsor  will provide  insurance  or indemnify  (legal  and financial  coverage),  the Investigatory/  
Institution  against  claims  arising  from  the study,  insurance  covering  the cost of treatment  of the 
subjects  in the event  of clinical ‐trial‐related  injuries,  in accordance  with national  regulations,  except  
for claims  that arise  from  malpractice,  negligence,  or non‐compliance  with the protocol.  The 
certific ate of insurance  and coverage  will be provided  upon  request.  
[ADDRESS_1195106]  to the right  of the Investigator  or any 
member  of his/her  staff to publish  the results  in accordance  with the publication  procedure  to be 
defined  in the clinical  trial agreement.  
Independent  analysis  and/or  publication  of this data by [CONTACT_857814]/her  
staff are permitted  subject  to obtaining  the prior  written  consent  of Sponsor.  
Written  permission  to the Investigator  will be contingent  on the review  by [CONTACT_857815]      
 
22-2-2022Page 82 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐[ADDRESS_1195107]  proprietary  information  and to 
provide  comments  based  on information  that may not yet be available  to other  parties.  
21 STATEMENT  OF  COMPLIANCE  
The trial will be conducted  in compliance  with the approved  protocol,  Declaration  of Helsinki,  ICH 
GCP and local  applicable  regulatory  requirement(s).  
The clinical  trial shall not begin  until the required  approval  or favourable  opi[INVESTIGATOR_857738]/IRB  
has been  obtained  and, if applicable,  any local  or national  regulatory  authority  approvals  or 
notifications  have  been  obtained.  
The Sponsor  has obtained  clinical  trial insurance  that will cover  expenses  in the event  of any physical  
injury  resulting  from  research  procedures.  
22  APPENDICES  
Appendix  1: ASEPSIS  Score  Assessment  
Appendix  2: Modified  Vancouver  Scar Scale  
Appendix  3: PK instructions  for Collection  and Processing  
Appendix  4: Surgical  Site Assessment  Questionnaire  
Appendix  5: Charlson  Co‐Morbidity  Index  
Appendix  6: Document  Change  History         
 
22-2-2022Page 83 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
23  REFERENCES  
1.  Carney  MJ, Weissler  JM, Fox JP, Tecce  MG, Hsu JY, Fischer  JP. Trends  in open  abdominal  
surgery  in the United  StatesObservations  from  9,950,759  discharges  using  the 20092013  
National  Inpatient  Sample  (NIS)  datasets.  The  American  Journal  of Surgery . 2017;214(2):287 ‐
292. doi:10.1016/j.amjsurg.2017.01.[ADDRESS_1195108]  Frequent  Operating  Room  Procedur es 
Performed  in U.S. Hospi[INVESTIGATOR_600],  20032012:  Statistical  Brief  #186.  2006.  
http://europepmc.org/abstract/med/25695123.  Accessed  November  5, 2019.  
3.  Bratzler  DW, Dellinger  EP, Olsen  KM, et al. Clinical  Practice  Guidelines  for Antimicrobial  
Prophylaxis  in Surgery.  Surgical  Infections . 2013;14(1):73 ‐156. doi:10.1089/sur.2013.9999  
4.  Mihaljevic  AL, Müller  TC, Kehl V, Friess  H, Kleeff  J. Wound  Edge  Protectors  in Open  Abdomin al 
Surgery  to Reduce  Surgical  Site Infections:  A Systematic  Review  and Meta ‐Analysis.  PLOS  ONE. 
2015;10(3):e0121187.  doi:10.1371/journal.pone.0121187  
5.  Alonso ‐Isa M, Medina ‐Polo J, Lara‐Isla A, et al. Surgical  wound  infection  in urology.  Analysis  of 
risk factors  and associated  microorganisms.  Actas  Urológicas  Espaæolas  (English  Edition) . 
2017;41(2):109 ‐116. doi:10.1016/j.acuroe.2016.12.005  
6.  Aga E, Keinan ‐Boker  L, Eithan  A, Mais  T, Rabinovich  A, Nassar  F. Surgical  site infections  after  
abdominal  surgery:  incidence  and risk factors.  A prospective  cohort  study.  Infectious  Diseases . 
2015;47(11):761 ‐767. doi:10.3109/23744235.2015.1055587  
7.  Azoury  SC, Farrow  NE, Hu Q, et al. Postoperative  abdominal  wound  infection   epi[INVESTIGATOR_623],  
risk factors,  identification,  and management.  In: ; 2015.  doi:10.2147/cwcmr.s62514  
8.  Fry DE. The Prevention  of Surgical  Site Infection  in Elective  Colon  Surgery.  Scientifica.  
doi:10.1155/2013/896297  
9.  Avkan ‐Oğuz V, Baykam  N, Sökmen  S, et al. Recommendations  for intra ‐abdominal  infections  
consensus  report.  Ulus  Cerrahi  Derg . 2016;32(4):306 ‐321. doi:10.5152/UCD.2016.3688  
10.  Pellegrini  JE, Toledo  P, Soper  DE, et al. Consensus  Bundle  on Prevention  of Surgical Site 
Infections  After  Major  Gynecologic  Surgery.  Journal  of Obstetric,  Gynecologic  & Neonatal  
Nursing . 2017;46(1):100 ‐113. doi:10.1016/j.jogn.2016.10.003  
11.  Steiner  HL, Strand  EA. Surgical ‐site infection  in gynecologic  surgery:  pathophysiology  
and prevention.  American  Journal  of Obstetrics  and  Gynecology . 2017;217(2):121 ‐128. 
doi:10.1016/j.ajog.2017.02.014  
12.  Mulder  T, Kluytmans  J. All care bundles  are equal,  but some  are more  equal  than  others.  
Annals  of Laparoscopic  and  Endoscopic  Surgery . 2017;2(9).  doi:10.[ZIP_CODE]/4150      
 
22-2-2022Page 84 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
13.  Huiras  P, Logan  JK, Papadopoulos  S, Whitney  D. Local  Antimicrobial  Administration  for 
Prophylaxis  of Surgical  Site Infections.  Pharmacotherapy:  The  Journal  of Human  Pharmacology  
and  Drug  Therapy . 2012;32(11):1006 ‐1019.  doi:10.1002/phar.1135  
14.  Bennett ‐Guerrero  E, Pappas  TN, Koltun  WA, et al. GentamicinCollagen  Sponge  for Infection  
Prophylaxis  in Colorectal  Surgery.  New  England  Journal  of Medicine . 2010;363(11):1038 ‐1049.  
doi:10.1056/NEJMoa1000837  
15.  Bennett ‐Guerrero  E, Berry  SM, Bergese  SD, et al. A randomized,  blinded,  multicenter  trial of a 
gentamicin  vancomycin  gel (DFA ‐02) in patients  undergoing  abdominal  surgery.  The  American  
Journal  of Surgery . 2017;213(6):1003 ‐1009.  doi:10.1016/j.amjsurg.2016.10.007  
16.  McHugh  SM, Collins  CJ, Corrigan  MA, Hill ADK,  Humphreys  H. The role of topi[INVESTIGATOR_857739].  J Antimicrob  Chemother . 
2011;66(4):693 ‐701. doi:10.1093/jac/dkr009  
17.  Edmiston  CE, Leaper  D, Spencer  M, et al. Considering  a new domain  for antimicrobial  
stewardship:  Topi[INVESTIGATOR_857740].  American  Journal  of Infection  
Control . 2017;45(11):1259 ‐1266.  doi:10.1016/j.ajic.2017.04.012  
18.  Gschwend  MH, Martin  W, Erenmemi şoğlu A, et al. Pharmacokinetics  and Bioequivalence  Study  
of Doxycycline  Capsules  in Healthy  Male  Subjects.  Arzneimittelforschung . 2007;57(6):347 ‐351. 
doi:10.1055/s ‐0031 ‐1296629  
19.    Ongom  PA, Kijjambu  SC. Antibiotic  Prophylaxis  in Colorectal  Surgery:  Evolving  Trends.  Journal  
of Molecular  Pharmaceutics  & Organic  Process  Research . 2013;1.  doi:10.4172/2329 ‐
9053.1000109  
20.   Mehta  CR, Pocock  SJ. Adaptive  Increase  in Sample  Size when  Interim  Results  are Promising:  A 
Practical  Guide  with Examples.  Statist.  Med. 2000;  00:1[ZIP_CODE]  
 
 
 
      
 
22-2-2022Page 85 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
APPENDIX  1: ASEPSIS  SCORE  ASSESSMENT  
ASEPSIS  provides  numerically  score  during  an inspection  of the surgical  site. The final score  is being  
interpreted  to severity  of wound  appearance  and the clinical  consequences  of the infection.  
 
 
 
  
    
 
22-2-2022Page 86 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
APPENDIX  2: MODIFIED  VANCOUVER  SCAR  SCALE  
The Modified  Vancouver  Scar Scale  documents  the change  in scar appearance,  through  a numeric  
assessment  of four characteristics  of the wound.  
Lower  scores  indicate  better  wound  healing.  
 
Modified  Vancouver  Scar Scale  
Vascularity   Normal  
Pi[INVESTIGATOR_857741]  0 
1 
2 
3 
Pi[INVESTIGATOR_857742]  0 
1 
2 
3 
Pliability   Normal  
Supple  
Yielding  
Firm 
Adherent  0 
1 
2 
3 
4 
Height   Flat 
1‐2 mm 
3‐4 mm 
5‐6 mm 
> 6 mm 0 
1 
2 
3 
4 
 
 
      
 
22-2-2022Page 87 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
APPENDIX  3: PK  INSTRUCTIONS  FOR  COLLECTION  AND  PROCESSING  
 
The following  instructions  must  be followed  for the collection  of plasma  PK samples.  
1. At the allotted  time points,  draw  at least  [ADDRESS_1195109]  8 times  to allow  the specimen  to mix with the anticoagulant  in the 
tube  to avoid  clotting.  
3. Store  vacutainer  at ambient  temperature  prior  to centrifugation.   Proceed  to centrifugation  
within  18 hours  of blood  draw.  
4. Centrifuge  the tube(s)  at 2000  rpm (equivalent  to 3000  g) for 15 minutes.  
5. Using  a disposable  pi[INVESTIGATOR_8462],  transfer  the supernatant  (plasma)  layer  into 2 pre‐labelled  poly‐
propylene  2ml Eppendorf  tubes.  Try to keep  equal  amounts  of plasma  with the 2 tubes.    
 Mark  these  2 tubes  as:  A (primary)  and B (back ‐up), complete  the appropriate  label 
and place  them  onto  the 2ml tubes.   
6. Plasma  samples  must  be stored  at or below  ‐20C or below  
 
PK  Sample  Specimen  Handling  
1. Two cryotubes  (A and B) are obtained  for each  sample  time point.   Shipments  must  be split 
(e.g. Set A is sent first, followed  by [INVESTIGATOR_662335] B, dispatched  24h to 72h later).  
2. It is import ant that SHIPMENTS  MUST  NOT CONTAIN  BOTH  CRYOTUBES  A and B for the same  
time point,  in the same  shipment.   
3. Specimen  collection  times  must  be documented  in the source  records.   These  must  be kept 
up to date.  
4. Cryotubes  should  be packed  in groups  with samples  A and B packed  separately , according  to 
subject  number  and stored  at ‐20C prior  to shipment  to: ICON  Laboratories,  Inc. 
Back ‐up  Sample  Shipment   
Back ‐up samples  are to be shipped  once  ICON  Laboratory  confirms  the primary  samples  have  been  
received.  ICON  Laboratory  will send  an e‐mail alert  to the site confirming  receipt  of the primary  
samples.  Back ‐up samples  should  be handled  and shipped  in the same  manner  as the primary  
samples.   
 
 
      
 
22-2-2022Page 88 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
Organisms  identified  by [CONTACT_857816]  (i.e. removal  of pi[INVESTIGATOR_857743])    
A deep  incision  that spontaneously  dehisces , or is deliberately  opened  or aspi[INVESTIGATOR_857744] a physician     
Drainage  of pus from  the wound  under  local  anesthetic          
Drainage  of pus from  the wound  under  general  anesthetic     
An abscess  or other  evidence  of infection  involving  the  deep  incision  that is detected  
on gross  anatomical  or histopathologic  exam,  or imaging  test   
Antibiotic  treatment  required  (due to incision  infection)     
Stays  as inpatient  > 14 days (due to incision  infection)          
Diagnosis  of a Superficial  incisional  SSI by  [CONTACT_857817]  
 
      
 
22-2-2022Page 90 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
APPENDIX  5: CHARLSON  CO ‐MORBIDITY  INDEX  (CCI)  
Predicts  10‐year survival  in patients  with multiple  comorbidities.  
Medical  Condition   Score  
Age  
<50 years  
5059  years  
6069  years  
7079  years  
g80 years   
0 
+1 
+2 
+3 
+4 
Myocardial  infarction  
History  of definite  or probable  MI (EKG  changes  and/or  enzyme  changes)  
No 
Yes  
 
0 
+1 
Chronic  Heart  Failure  
Exertional  or paroxysmal  nocturnal  dyspnea  and has responded  to digitalis,  diuretics,  or after ‐
load reducing  agents  
No 
Yes  
 
 
0 
+[ADDRESS_1195110] by[CONTACT_857818],  history  of gangrene  or 
acute  arterial  insufficiency,  or untreated  thoracic  or abdominal  aneurysm  (g6 cm) 
No 
Yes  
 
 
0 
+1 
CVA  or  TIA  
History  of a cerebrovascular  accident  with minor  or no residua  and transient  ischemic  attacks  
No 
Yes  
 
0 
+1 
Dementia  
Chronic  cognitive  deficit  
No 
Yes  
 
0 
+1 
COPD  
No 
Yes  
0 
+1 
Connective  tissue  disease  
No 
Yes  
0 
+1 
Peptic  ulcer  disease  
Any history  of treatment  for ulcer  disease  or history  of ulcer  bleeding  
No 
Yes  
 
0 
+1 
Liver  disease  
Severe  = cirrhosis  and portal  hypertension  with variceal  bleeding  history,  moderate  = cirrhosis  
and portal  hypertension  but no variceal  bleeding  history,  mild = chronic  hepatitis  (or cirrhosis  
without  portal  hypertension)   
 
 
     
 
22-2-2022Page 91 of 99 Effective
 
D‐PLEX  311  Clinical  Trial  Protocol  
Legacy  Document  Number:  CL‐0027  
 
CONFIDENTIAL  
Medical  Condition   Score  
None  
Mild 
Moderate  to severe  0 
+1 
+3 
Diabetes  mellitus  
None  or diet‐controlled  
Uncomplicated  
End‐organ  damage   
0 
+1 
+2 
Hemiplegia  
No 
Yes  
0 
+2 
Moderate  to  severe  Chronic  Kidney  Disease  
Severe  = on dialysis,  status  post kidney  transplant,  uremia,  moderate  = creatinine  >3 mg/dL  
(0.27  mmol/L)  
No 
Yes  
 
 
0 
+2 
Solid  tumor  
None  
Localized  
Metastatic   
0 
+2 
+6 
Leukemia  
No 
Yes  
0 
+2 
Lymphoma  
No 
Yes  
0 
+2 
AIDS  
No 
Yes  
0 
+6 
Is this  a COVID ‐19  patient?  
For research  purposes  only;   
answer  does  NOT impact  results.  
Confirmed  positive  
Suspected  
Unlikely  
Confirmed  negative   
 
Summary  score    
 
     
 
22-2-2022Page 92 of 99 Effective
D-PLEX 311 Clinical Trial Protocol P-000066
Protocols Version 6.0
22-2-2022Page 99 of 99 EffectiveDocument Signatures
Participant Name [CONTACT_857824]
(Clinical 
Development 
Manager)ApproverSend to QA 
Approval2022-02-21 17:23
Lital Weinfeld 
Bergman (Clinical 
Operations 
Manager)ApproverSend to QA 
Approval2022-02-21 18:11
Dalit Hazan (VP 
R&D and RA)ApproverSend to QA 
Approval2022-02-21 18:30
Noam Emanuel 
(CSO)ApproverSend to QA 
Approval2022-02-22 09:45
Maria Rubin (VP 
Quality)QA Approver Approve Document 2022-02-22 10:02